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ABSTRACT 
The human immunodeficiency virus type 1 (HIV-1) group M is responsible for the HIV 
pandemic and has great genetic variability. The main subtypes and circulating 
recombinant forms belonging to this group differ in their worldwide distribution, their 
disease progression patterns, as well as in their coreceptor use phenotype distributions. 
The coreceptor use phenotypes of HIV-1 are based on which coreceptor the virus uses 
for cell entry, with the two main coreceptors being CCR5 and CXCR4, corresponding 
accordingly to the R5 and X4 phenotype. The R5 phenotype is found early in the 
infection while the X4 emerges over time and is associated with disease progression. 
The main determinant of coreceptor use in HIV-1 is the third variable region (V3) of 
the HIV-1 envelope glycoprotein 120, which is the docking surface protein that 
attaches itself to the primary CD4 receptor and a coreceptor during cell entry.   
 
In papers I and II, observations were made regarding the role of the V3 glycan and V3 
charge in coreceptor use, based on sequences belonging to different HIV-1 subtypes 
retrieved from the Los Alamos HIV Sequence database, which contains sequences 
submitted from infected individuals all over the world.  The V3 glycan was shown in 
paper I to be strongly associated with CCR5 use while a net high charge acquired from 
different positions in the V3 was shown in paper II to be important for CXCR4 use. As 
a result, a model adjustable for different subtypes was created, referred to as the glycan-
charge model, for distinguishing between the coreceptor use phenotypes based on their 
biological properties that can be deduced from the V3 amino acid sequence.  
 
CCR5 inhibitors are a class of antiretroviral drugs that target the CCR5 coreceptor, 
thereby blocking the entry of R5 viruses into cells. However, prior to their 
administration it is important to verify that a patient does not harbour CXCR4-using 
variants, which could otherwise be selected for. Biological methods of coreceptor use 
determination are expensive and time-consuming. Hence, coreceptor use prediction 
algorithms, which can predict the coreceptor use from HIV-1 V3 sequences, could help 
to make CCR5 inhibitors more universally accessible, but their prediction accuracy 
needs to be improved.  
 
Infections with HIV-1 subtype C, which is the dominating subtype worldwide and in 
sub-Saharan Africa, are usually associated with low CXCR4 use, but several studies 
have found an increased CXCR4 use among treatment failure patients. To investigate 
this further, 24 treatment failure patients infected with subtype C in Botswana were in 
paper III compared with 26 treatment-naïve patients with regard to coreceptor use, 
which was determined using the coreceptor use prediction algorithm Geno2pheno with 
a false positive cut-off rate of 10 % as well as the glycan-charge model on population 
sequences. Increased CXCR4 use was found in the treatment-experienced group, 
suggesting that treatment with the only CCR5 inhibitor in clinical use to date, 
maraviroc, would be less suitable in this group, which is of special significance since 
maraviroc is mainly used as a salvage therapy drug.  
 
Finally, in paper IV all currently available coreceptor use prediction algorithms, 
including the glycan-charge model algorithm, were evaluated from a CCR5 inhibitor 
  
treatment perspective in a uniquely suited testing material, which consisted of V3 
sequences of the major HIV-1 subtypes retrieved from the Los Alamos HIV Sequence 
database. A rigorous scrutiny of the original source articles was performed to verify 
that the reported coreceptor use was determined biologically. The results showed that 
learning algorithms were found to perform well in all studied subtypes, along with 
subtype-specific complex rule algorithms.  
 
In summary, papers I and II elucidated the biological properties of coreceptor use in 
different subtypes, which could be determined using the V3 amino acid sequence, 
paper III applied this knowledge to help investigate the increased CXCR4 use in 
subtype C infected treatment failure patients, while paper IV compared all current 
coreceptor use prediction algorithms, including the glycan-charge model based on the 
observations in papers I and II, and applied in paper III, from a CCR5 inhibitor 
treatment perspective. 
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AMINO ACID IUPAC CODES 
 
 
Code Abbreviation Amino Acid 
 
   A         Ala  Alanine 
   B         Asx  Aspartic acid or Asparagine 
   C         Cys  Cysteine 
   D         Asp  Aspartic acid 
   E         Glu  Glutamic acid 
   F         Phe  Phenylalanine 
   G         Gly  Glycine 
   H         His  Histidine 
   I         Ile  Isoleucine 
   K         Lys  Lysine 
   L         Leu  Leucine 
   M         Met  Methionine 
   N         Asn  Asparagine 
   P         Pro  Proline 
   Q         Gln  Glutamine 
   R         Arg  Arginine 
   S         Ser  Serine 
   T         Thr  Threonine 
   V         Val  Valine 
   W         Trp  Tryptophan 
   X         Xaa  Any amino acid 
   Y         Tyr  Tyrosine 
   Z         Glx  Glutamine or Glutamic acid 
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1 BACKGROUND 
 
1.1 HIV-1 BASICS 
One of the greatest pandemics of our time is caused by the human immunodeficiency 
virus (HIV), which is the etiological agent of acquired immunodeficiency syndrome 
(AIDS), a condition where the patient’s immune system deteriorates slowly, eventually 
allowing the onset of opportunistic infections, which ultimately lead to premature death 
if no interventions are made. 
 
1.1.1 Origins 
HIV is closely related to the simian immunodeficiency virus (SIV), which primarily 
infects nonhuman primates, including chimpanzees (Pan troglodytes troglodytes), 
gorillas (Gorilla gorilla), and sooty mangabeys (Cercocebus atys), inducing a condition 
reminiscent of AIDS. It is believed that HIV is of simian origin, and is the result of 
multiple cross-species transmissions of SIV from nonhuman primates to humans [1, 2]. 
Four different cross-species transmission events of SIV from chimpanzees and gorillas 
gave rise to HIV type 1 (HIV-1) [1-4], while the less pathogenic HIV type 2 (HIV-2), 
which is rarely found outside of West Africa [5], was the result of eight different cross-
species transmissions of SIV to humans from sooty mangabeys [1, 2, 6, 7]. The most 
likely mode of transmission in these instances was due to contact with blood or other 
bodily fluids of nonhuman primates infected with SIV during the hunt or the handling 
of primate bushmeat [1, 2, 8, 9], while bites or other wounds inflicted from pet 
nonhuman primates constitute another possible mode of transmission [2, 9]. Despite the 
occurrence of multiple cross-species transmission events of SIV, only one of these, the 
origin of the major HIV-1 subgroup, HIV-1 group M, accounts for the HIV-1 pandemic 
[1, 2, 9]. 
 
1.1.2 Pandemic 
 
Figure 1. Adults and children estimated to be living with HIV in 2012. Credit: UNAIDS/ 
ONUSIDA 2013 [10]. 
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The first emergence of HIV-1 group M has been estimated using phylogenetical and 
statistical analyses to have occurred in 1931 (confidence interval of 1915-1941) [11], or 
even earlier in 1908 (1884-1924) [12]. The most probable location of the early 
epidemic is considered to have been Léopoldville [1, 9], now known as Kinshasa, the 
capital city of the Democratic Republic of the Congo, where also the earliest samples of 
HIV-1 group M were found, dating from 1959 [13] and 1960 [12]. Kinshasa was at the 
time a growing community due to colonial administration and trade, and was the largest 
city in west central Africa where urban lifestyle was continually on the increase, which 
probably facilitated the spread of the epidemic [1, 9, 12, 13].  
 
The AIDS epidemic was not brought to global attention until decades later in 1981, 
when opportunistic infections as well as uncommon malignancies started emerging in 
young male homosexuals in the US [14, 15]. Cases were also identified among 
intravenous drug users, Haitians, and hemophiliacs, and the Center for Disease Control 
named the new disease acquired immunodeficiency syndrome or AIDS, in 1982 [15]. 
In 1983, the cause of AIDS was identified to be a new human retrovirus [16, 17], at 
first known by the name human T-cell lymphotropic virus type III (HTLV-III), but 
subsequently renamed human immunodeficiency virus (HIV) in 1986 by the 
International Committee of the Taxonomy of Viruses [18]. The first blood test for the 
detection of HIV [19, 20] was approved for screening blood donors by the U.S Food 
and Drug Administration (FDA) in 1985 [15], while the first drug against HIV 
infection arrived in 1987 in the form of the cancer drug zidovudine (AZT), albeit the 
treatment was not very successful due to the quick emergence of drug-resistant variants 
[15]. The morbidity and mortality rates remained high until the turning point came in 
1996 when the triple drug regimen combination therapy was introduced [21-23], known 
as Highly Active Antiretroviral Treatment (HAART), transforming AIDS from a fatal 
disease into a somewhat controllable condition [15]. Nevertheless, the antiretroviral 
treatment continued to be cumbersome and wrought with side effects for years to come 
until new and improved drug regimens were developed during the last decade [24-26]. 
This development has improved the quality of life and considerably increased the life 
expectancy of HIV-infected patients in high-income, industrialized countries [27] 
where the latest treatment is readily available as opposed to in low-income countries 
[28], where the majority of afflicted patients reside [10]. 
 
Currently, 35.3 million adults and children are estimated to be living with HIV with 25 
million, the absolute majority, located in Sub-Saharan Africa (Figure 1) [10]. In 2012, 
1.6 million people died of AIDS, while 2.3 million became newly infected [10], 
indicating the continual endurance of the pandemic, with different factors contributing 
to its sustainment, such as drug availability [28], lack of a vaccine [15, 29], 
socioeconomic conditions [30, 31], and risk-behaviour [32].  
 
1.1.2.1 Botswana 
Botswana is a sub-Saharan country where 17.6 % of the population aged above 18 
months is infected with HIV, while the HIV prevalence among adults is 25 % and 
among pregnant women is as high as 30.4 % [33], rendering Botswana the country with 
the second-highest infection rate in the world [34]. As a result of the high HIV 
mortality and infection rates, the life expectancy in Botswana has radically decreased 
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[33]. In 2001, Botswana adopted the United Nations General Assembly Special Session 
on HIV and AIDS (UNGASS) Declaration of Commitment, leading among other 
things to the introduction of a national antiretroviral treatment program in 2002 [33]. 
Since then, the mortality rate has been reduced by 60 %, and 95 % receive antiretroviral 
treatment of those who are eligible for it [33]. 
 
1.1.3 Structure 
 
Figure 2. The structure of the HIV-1 virion. Adapted with permission from an illustration by 
Peter Clevestig.  
 
HIV-1 is a Lentivirus that belongs to the Retroviridae family, which is distinguished by 
the presence of a reverse transcriptase enzyme. A mature virion (Figure 2) is roughly 
145 nm (± 25 nm) in diameter [35] and consists of a host-derived lipid bilayer (the 
envelope) and a truncated cone-shaped capsid (p24). The components of the capsid are 
the enzymes reverse transcriptase (p66/p51), integrase (p32), and protease (p11), the 
nucleocapsid core proteins (p7, p9), tRNA molecules necessary for primer function 
during reverse transcription, and the RNA genome, which consists of two non-
covalently-linked, positive sense RNA strands. The membrane associated matrix 
protein (p17) is found between the capsid and the envelope, while the trimeric spikes 
exposed on the surface of the virion consist of the docking glycoprotein (gp120) and 
the transmembrane fusion glycoprotein (gp41). Since the envelope is derived from the 
host cell membrane, other host specific proteins are also present on the surface, such as 
the major histocompatibility complex (MHC) [36] and intercellular adhesion molecule-
1 (ICAM-1) [37].  
  
1.1.4 Genome 
As mentioned above, the HIV-1 genome is diploid, with two identical positive sense 
RNA strands, each approximately 9-10 kilobases long. The 5’ end of each strand has a 
methylated cap and the 3’end a poly-A tail, with long terminal repeat regions (LTRs) at 
both ends, which include promoter and enhancer sequences, as well as the primer 
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binding sequence (PBS), to which tRNA molecules associate that initiate reverse 
transcription. [38] 
 
Figure 3. The HIV-1 genome. Adapted with permission from [39]. 
 
The genome has multiple open reading frames, encoding the three main structural 
polyproteins Gag (group antigen), Pol (polymerase), and Env (the envelope 
glycoproteins), but also a number of accessory and regulatory proteins (Figure 3). The 
gag gene encodes the matrix protein (MA), which is important for virion assembly and 
facilitates the transport of complementary DNA to the host cell’s nucleus [40], the 
capsid protein (CA), and the nucleocapsid proteins (NC), which coat the viral RNA and 
are involved in its delivery during the virus assembly process [38]. The pol gene 
encodes the three enzymes, reverse trancriptase (RT), which transcribes the genomic 
RNA into complementary DNA (cDNA), integrase (IN), which integrates the cDNA 
with the host cell chromosomal DNA in the nucleus, and protease (PR), which 
completes the virion’s maturation by cleaving the Gag-Pol polyprotein in the already 
assembled virion [38]. The env gene encodes the 160 kD glycoprotein gp160, which 
consists of the docking surface protein (SU) gp120 and the transmembrane (TM) fusion 
protein gp41, which stay non-covalently associated and form the trimeric spikes that 
are interspersed on the virion’s surface [41]. Gp120 is involved in the cell attachment 
process through its binding to the primary receptor CD4 and subsequent to a 
conformational change in the spike structure, to one of several possible coreceptors. 
Coreceptor binding results in a second conformational change, which allows gp41 to 
mediate fusion with the cell membrane, enabling the virion to enter the cell [38].  
 
The regulatory proteins of HIV-1 are Tat (Transactivator of transcription) and Rev 
(Regulator of virion expression). The function of Tat is to enhance the rate of 
transcription, while Rev facilitates the transport of spliced and full-length RNA from 
the cell nucleus to the cytoplasm, where translation and assembly of new virions take 
place [38].  
 
HIV-1’s accessory proteins comprise Nef (Negative factor), Vif (Virion infectivity 
factor), Vpr (Viral protein R), and Vpu (Viral protein U). Nef increases viral infectivity 
and is of importance for disease progression and viral spread. One of its main functions 
is to downregulate CD4 and MHC class I expression on the host cell surface, thereby 
evading detection by cytotoxic T cells [42].Vif is also important for infectivity. In 
particular, Vif induces the degradation of the antiviral factor APOBEC3G, thereby 
preventing APOBEC3G from incorporating itself into HIV-1 virions and interfering 
with the replication process [43]. Vpr has multiple functions, including a role in nuclear 
import of the pre-integration complex and cell growth arrest [38]. Vpu exhibits an 
antagonizing effect on tetherin, thereby preventing tetherin from inhibiting HIV-1 
virion release from the cell [44]. Interestingly, Vpu is not encoded by HIV-2, which 
instead encodes Vpx (Viral protein X), which is absent in HIV-1. The function of Vpx 
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in HIV-2 involves the degradation of SAMHD1, which interferes with the reverse 
transcriptase step of lentiviruses [45]. 
 
1.1.5 Replication Cycle 
 
Figure 4. The HIV-1 replication cycle. Reproduced with permission from [46]. 
 
One HIV-1 replication cycle (Figure 4) takes on average approximately 1-2 days [47]. 
HIV-1’s primary target cells are CD4 positive T-cell lymphocytes [16, 17, 48], as well 
as other CD4-expressing cells, such as macrophages, dendritic cells and microglia [48-
51]. 
 
1.1.5.1 Attachment, binding and entry 
The entry process of HIV-1 into a host cell can be broken down into four steps [52]. 
The first step is the binding of gp120 to CD4, the primary receptor [53, 54]. The 
exterior envelope glycoprotein gp120 forms heterodimers with the transmembrane-
anchored fusion protein gp41 and together they constitute the heavily glycosylated 
trimeric spike on HIV-1’s surface. One subunit of gp120 consists of five constant 
regions (C1-C5) interspersed with five variable regions (V1-V5), out of which four 
form flexible loop structures [52]. As a consequence of binding to CD4, a 
conformational change is induced in gp120 where V1/V2 and then V3 are rearranged, 
leading to the exposure of coreceptor binding determinants. These determinants consist 
mainly of the V3 loop [55, 56], but the bridging sheet, a four-stranded β sheet formed 
after gp120’s binding to CD4, also plays a role in the coreceptor binding process [57-
59]. This enables the second step, the interaction of gp120 with a coreceptor, usually 
the C-C chemokine receptor type 5 (CCR5) [60-62] or C-X-C chemokine receptor 
type 4 (CXCR4) [63, 64], allowing the exposure of the hydrophobic gp41 fusion 
peptide. The third step involves the “surfing” of the virus across the surface with the 
help of host cell machinery, in an attempt to find the optimal location for fusion with 
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the cell membrane [65]. Finally, the fourth step comprises the actual fusion. The gp41 
fusion peptide is inserted into the cell membrane, thereby locking the viral and cell 
membranes together. This facilitates the fusion peptide in each gp41 subunit of the 
trimer to form a six-helix bundle, where the carboxy-terminal helical regions remain 
close to the viral membrane while the opposing amino-terminal helical regions stay 
close to the cell membrane [66, 67]. Consequently the six-helix bundle brings the 
membranes together, allowing the fusion of the virion with the cell membrane via the 
formation of a fusion pore, ensuing in the insertion of the viral core into the cytoplasm, 
where the process of uncoating starts [52].  
 
1.1.5.2 Reverse transcription and integration 
When the viral core has been released into the cytoplasm, the virion is uncoated, 
possibly with the aid of cyclophillin A, a cellular chaperon protein associated with the 
capsid [68]. Simultaneously, the reverse transciption complex is formed, containing 
MA, CA, NC, IN, Vpr, tRNA and the reverse transcriptase, RT [69]. Reverse 
transcription is initiated with the help of tRNA (Lys3) acting as a primer at the 5’ end 
of the single-stranded RNA genome. The DNA polymerase function of the RT is 
responsible for creating a complimentary negative sense DNA strand (added to the 3’ 
end of the tRNA molecule), while the RNase H function of the RT subsequently 
degrades the template RNA. The newly synthesized DNA strand is transferred to the 3’ 
end of the viral RNA where the direct repeats section (R) is located, allowing for the 
continuation and completion of the negative sense DNA strand synthesis 
simultaneously with the RNA degradation. The RNA strand contains a purine rich 
sequence called the polypurine tract, which prevents the RNase H from degrading the 
RNA further, thereby leaving an RNA sequence to serve as a primer for the synthesis 
of the positive sense DNA strand. The positive sense DNA strand is synthesized until 
18 nucleotides of the tRNA molecule are copied, allowing the RNase H to in turn 
degrade the tRNA molecule, leaving only an A ribonucleotide at the 5’ end of the 
negative sense DNA strand. The positive sense DNA strand is transferred to the primer 
binding site region of the negative sense DNA strand, which will be complimentary 
with the 18 nucleotides of the positive strand, copied from the tRNA molecule. This 
allows the two DNA strands to anneal to each other, followed by the completion of the 
synthesis of the negative and positive strands, forming a linear double-stranded DNA of 
the full genome with some extra length at each end, comprised of U3-R-U5, where U3 
was derived from the original RNA template’s 3’ end and U5 from its 5’ end. These 
U3-R-U5 regions constitute the long terminal repeats (LTR). [70] 
 
Late in the reverse transcription process, the reverse transcription complex is converted 
to a preintegration complex, which includes the integrase, IN and other viral proteins. 
The preintegration complex is actively imported to the cell nucleus, where IN removes 
two nucleotides from the 3’ ends of the double-stranded DNA, allowing these ends to 
target phosphodiester bonds on opposite ends of the aimed section of the host cell’s 
DNA, leading to the joining of the viral DNA’s 3’ ends to the host DNA’s 5’ ends. 
Subsequently, the unpaired two bases at the 5’ ends of the viral DNA are removed, 
allowing the ligation of these 5’ ends to the host DNA. IN catalyzes the processing of 
the 3’ ends and the DNA transfer stage, but other events are likely catalyzed with the 
help of cellular enzymes. The integration of viral DNA can occur at multiple locations 
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in the host genome, and the integrated DNA is called a provirus, which forms the basis 
of retroviral infection. [71] 
 
1.1.5.3 Transcription and translation 
The integrated provirus can remain latent or be transcribed by the host cell’s RNA 
polymerase II upon activation of the cell cycle, producing full-length mRNAs. The 
mRNAs are spliced in multiple ways [72-74], generating approximately 30 different 
transcripts. The early transcripts are multiply spliced to produce the regulatory proteins 
Tat and Rev, as well as the accessory protein Nef. Tat enhances the transcription 
process, Rev regulates the export of both spliced and unspliced mRNA to the 
cytoplasm, and Nef downregulates molecules on the cell surface such as CD4, which 
helps the virus to evade the immune system. The proteins Vpr, Vpu, Vif, and Env are 
produced from mRNAs that are singly spliced, while the unspliced mRNA transcript 
forms the Gag-Pol polyprotein. [75] 
 
HIV-1 uses free polyribosomes in the cytoplasm to translate its mRNA into proteins. 
As mentioned above, HIV-1 uses alternative splicing of mRNA to generate different 
proteins to make the best use of its relatively small genome. Ribosomal frameshifting is 
another strategy utilized by HIV-1 for this purpose, which allows the production of 
Gag-Pro-Pol polyproteins even though the gag and pol genes are in different open 
reading frames that nonetheless overlap [76], thereby also maintaining the correct ratio 
between produced Gag polyproteins and Gag-Pro-Pol polyproteins necessary for the 
regulation of the replication cycle and for the correct amount of monomers of 
replication enzymes to be packaged during the assembly of new virion particles [77]. 
The Env glycoprotein precursor, gp160, is translated from a bicistrionic mRNA, 
followed by co-translational modification in the lumen of the endoplasmic reticulum, 
where N-linked oligomannosyl carbohydrate residues are added and trimmed [78]. The 
gp160 precursor glycoprotein is then transported to the Golgi complex where gp160 is 
cleaved into gp120 and gp41 by cellular proteases and the N-linked glycans are 
modified to generate complex type carbohydrates [78]. After these maturation steps, the 
glycoproteins are transported to the cell surface where they will become part of the 
envelopes of budding virus particles. 
 
1.1.5.4 Assembly, release and maturation 
The assembly of the virion takes place at the cell membrane, where the envelope 
trimeric spikes have already been incorporated, intermingled with host cell surface 
proteins. The different domains of the Gag polyprotein direct the assembly process: 
MA binds to the cell membrane and recruits the envelope glycoproteins, CA facilitates 
the necessary protein-protein interactions and produces the capsid, and NC seizes the 
viral genome and acts as a nucleic acid chaperone to tRNA during its annealing to the 
genome as a primer. The different viral components are gathered into spherical 
immature particles, where the Gag polyproteins are attached to the envelopes and 
radially projected toward the centers of the particles. As the budding takes place, PR is 
activated, resulting in the cleavage of the Gag polyproteins into MA, CA, NC, and p6, 
and the Pol section of Gag-Pro-Pol polyproteins into RT, IN, and PR, converting the 
produced viral particles into mature virions capable of infecting and replicating in new 
host cells. [79] 
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1.1.6 Pathogenesis 
 
Figure 5. The natural time course of HIV-1 infection. Reproduced with permission from [47]. 
 
Exposure to HIV-1 at mucosal surfaces or through percutaneous inoculation can lead to 
infection [30]. The main modes of transmission are sexual, vertical, and by intravenous 
drug injections [30]. Blood transfusions are another possible source of transmission in 
countries where donated blood is not always screened properly for HIV. 
 
HIV-1 infection can be divided into different phases (Figure 5). The first is the eclipse 
phase, which lasts 1-2 weeks, when the virus spreads from the site of infection to other 
organs and tissues, such as CD4+ T cells in draining lymph nodes and gut-associated 
lymphoid tissue (GALT), where it is able to replicate [80]. During this stage, the virus 
cannot be detected in the blood, and the patient is asymptomatic, since the immune 
system has not yet mounted a proper response. The next 2-4 weeks mark the acute 
phase, also called the primary infection. Some patients become symptomatic during this 
stage with “flu-like” symptoms, such as fever, throat ache and enlarged lymph nodes. 
The virus levels in the blood peak during this period up to approximately 107 RNA 
copies/mL plasma, perhaps as a result of the lack of an early immune response and the 
increase in available CD4+ T cells as the immune system begins to mount an antibody 
and CD8+ T cell response against HIV-1. At the end of the acute phase, the virus levels 
in the blood drop dramatically, roughly 100-fold, coupled with the transitory decline of 
the amount of CD4+ T cells measured in the blood. [47] 
 
The acute phase is sometimes divided into Fiebig stages, which give an indication of 
the type of laboratory markers that can be used for diagnosis at the different time points 
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[81]. HIV-1 RNA is detectable in the blood by polymerase chain reaction (PCR) after 
about day 10 of the infection (Fiebig I), viral p24 antigen appears roughly after day 17 
(Fiebig II), while HIV-specific antibodies can be detected by a recombinant protein-
based enzyme-linked immunosorbant assay after approximately day 23 (Fiebig III) and 
by Western blot after day 26 (Fiebig IV) [81]. 
 
The acute phase is followed by the chronic phase, also known as “clinical latency”, 
which can last from ≈ 1 to 20 years, during which the patient is asymptomatic, and 
often unaware of the infection. During this time, the viral RNA levels are mostly fixed 
at around 1-100 000 copies/mL blood, referred to as the “set point”, but may also be 
gradually increasing. The CD4+ T cell count is close to normal levels at roughly 1000 
cells/µL, but may begin to progressively decline. [47] 
 
When CD4+ T cells have dropped to approximately 300-500 cells/µL, some symptoms 
of immunodeficiency may start to appear [82], but an HIV-infected patient is not 
considered to have AIDS until the CD4 count is below 200 cells/µL or if the patient has 
acquired an AIDS-defining illness, examples of which are the opportunistic infections 
Pneumocystis jirovecii pneumonia, esophageal candidiasis, and brain toxoplasmosis,  
and malignancies such as Kaposi’s sarcoma and Burkitt’s lymphoma [83-85]. During 
the AIDS stage, viremia steadily rises simultaneously with the decline of the CD4 
count, since the immune system can no longer control the infection. Without 
antiretroviral treatment at this point, the mortality rate is above 95 % and the patient 
will most likely die before long [47]. 
 
1.2 HIV-1 GENETIC VARIABILITY 
HIV-1 has a high genetic variability due to the error rate and the predisposition to 
retroviral recombination of the reverse transcriptase enzyme during replication, coupled 
with the high turnover of virions [86-89]. The single-step point mutation rate of HIV-1 
is ≈ 3 x 10-5 mutations per base per replication cycle [90], and about 1011 viral particles 
are likely generated daily [47].  
 
1.2.1 Groups 
HIV-1 can be further subdivided into groups (Figure 6), group M (major), N (non-M, 
non-O), O (outlier), and the more recently discovered group P [91]. All four groups are 
thought to be the result of separate cross-species transmission events [1], with group M 
and N originating from SIV in chimpanzees [3], group P from SIV in gorillas [91, 92], 
while the origins of group O are unknown, but a chimpanzee or gorilla SIV origin is 
likely [1, 2]. Only two cases have been found of Group P [91, 92] and 13 of group N [1, 
93], all being of Cameroonian origin. Group O represents less than 1 % of all HIV 
infections and is mainly found in Cameroon, Nigeria, and Gabon [94, 95]. Group M on 
the other hand represents the vast majority of HIV-1 infections with millions of people 
infected, and is responsible for the global spread of the infection, existing in almost 
every country [1, 2]. 
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Figure 6. HIV-1 groups and their phylogenetic relationship with SIV and HIV-2. Reproduced 
with permission from [96]. 
 
1.2.2 Subtypes 
HIV-1 group M is divided into subtypes based on their genetic similarity that are 
distributed differently geographically (Figure 7). There are nine subtypes designated 
with the letters A-D, F-H, J and K, as well as numerous recombinant forms. Subtypes E 
and I were during later analysis found to be recombinant, and were subsequently 
renamed accordingly to CRF01_AE and CRF04_cpx (or in some cases U for 
unclassified), respectively [97]. The amino acid level of variation within a subtype is 
between 8 and 17 %, but can be up to 30 %, while the level of variation between 
subtypes ranges from 17 to 35 %, but can be as high as 42 %, with the highest diversity 
observed in the env gene [98, 99]. Hence, subtypes B and D could due to their genetic 
similarity be potentially classified as the same subtype, but are not so owing to 
historical reasons [2]. 
 
Subtype C is the dominating subtype worldwide, responsible for more than 50 % of all 
HIV infections [96, 100]. Subtype C is responsible for nearly 100 % of all HIV 
infections in southern African countries such as South Africa, Zimbabwe, 
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Mozambique, Malawi, Swaziland and Botswana, but is also common in East Africa, as 
well as in India and Oceania [2]. Subtype B predominates in Australia, Western Europe 
and North America [101], and is perhaps hence the most studied subtype to date. It 
originated most likely in central Africa, but spread later through Haiti to MSM (men 
who have sex with men), intravenous drug user and hemophiliac populations in USA 
and Europe [102]. South America also has a large proportion of subtype B infections, 
along with subtype F infections. Subtype A is found among intravenous drug users in 
Eastern Europe, as well as in East African countries, such as Uganda, Kenya and 
Tanzania, where it co-circulates with subtypes C and D, together with various 
recombinant forms based on these three subtypes [2]. Subtype D is largely restricted to 
the East African countries Uganda, Kenya, South Sudan and Tanzania [103], as is 
subtype G to West Africa [96].  
 
 
Figure 7. The geographical distribution of HIV-1 group M subtypes. Reproduced with 
permission from [96].  
 
It has been suggested that the subtypes are not only differently distributed and 
genetically dissimilar, but also have varying transmission efficiency and differing 
disease progression [103]. Mother-to-child transmission in utero has been suggested to 
be preferential in subtype C compared to subtypes A and D [104, 105], perhaps due to 
increased vaginal shedding [105]. A study conducted in Senegal showed that females 
infected with subtype A were less prone to progress to AIDS compared to females 
infected with subtypes C, D and G [106], while a Swedish study on the other hand 
showed no difference in disease progression between patients infected with subtypes A, 
B, C and D [107]. Subtype D has nevertheless been associated with a faster disease 
progression compared to subtypes A, B, and/or C in several studies [108-112]. It has 
however been debated whether or not some of these observations are confounded by 
factors such as mode of transmission, host genetic factors, nutritional status and access 
to medical treatment [103].  
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1.2.3 Circulating Recombinant Forms 
The creation of circulating recombinant forms (CRFs) is the result of co-infection in the 
same individual with different subtypes, allowing a recombination of their genomes 
[103]. For a virus to be classified as a CRF, it needs to be found in at least three 
epidemiologically unlinked individuals. Viruses that are found in fewer individuals are 
designated as unique recombinant forms (URFs). There are at present 58 existing CRFs 
and innumerable reports of URFs. CRFs are named according to a number and letter 
system, where the number stands for the order in which the CRF was discovered and 
the letters stand for the subtypes that the CRF is a recombination of. For instance, 
CRF01_AE was the first recombinant form to be discovered (hence the number 01), 
and is comprised of gag and pol genes from subtype A and an env gene from subtype E 
(as mentioned above, subtype E is no longer considered a separate subtype and all its 
sequences were consequently classified as CRF01_AE). If a CRF is a combination of 
three or more subtypes, the letter code in the name is replaced with “cpx”, as is for 
instance the case with CRF04_cpx (previously subtype I). [2] 
 
The two most common CRFs are CRF01_AE, which is found primarily in south-east 
Asia, and CRF02_AG, which predominates in West Africa causing up to 50-80 % of 
the HIV infections in that region. Among intravenous drug users, CRF03_AB is 
common in Eastern Europe and CRF07_BC and CRF08_BC in China, while 
CRF06_cpx possibly represents as much as 20-50 % of all HIV infections in the West 
African countries Togo, Burkina Faso, Niger and Nigeria. [2]  
 
CRF01_AE has been associated with a faster disease progression compared to other 
CRFs and subtype B in Singapore [113], as well as in Thailand compared to subtype B 
infections in developed countries [114]. A Thai study on intravenous drug users found a 
higher probability of transmission of CRF01_AE compared to subtype B, but could not 
exclude that epidemiological, virological or host factors affected the results [115]. 
CRF02_AG has on the other hand not been associated with faster disease progression 
compared with other CRFs and subtypes in western and west-central Africa [116]. 
However, according to a more recent study conducted in Guinea-Bissau, patients 
infected with the A3/CRF02_AG  (recombinant form between sub-subtype A3 and 
CRF02_AG) progressed faster to AIDS compared to patients infected with sub-subtype 
A3, suggesting that disease progression may vary among A-like subtypes/CRFs [117].  
 
1.3 HIV-1 PHENOTYPE CLASSIFICATIONS 
HIV-1 has since its discovery been classified into biological phenotypes in different 
ways. Even though these classifications overlap with each other, they are not 
synonymous [118], and ought therefore not to be used interchangeably. 
 
1.3.1 Cell Tropism 
In 1987, two genetically related but distinct HIV variants in the same patient were 
isolated from brain tissue and cerebrospinal fluid, respectively. Both viruses could 
infect peripheral blood mononuclear cells (PBMC), but only the virus from the brain 
tissue could infect macrophages and monocytes, indicating that genetic variation of 
HIV within a patient may lead to altered cell tropism of the patient’s viruses [119]. 
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Apart from in vivo observations, it could also be shown in vitro that HIV isolated from 
PBMCs could be co-cultivated with differentiated macrophages or phytohemagglutinin 
stimulated CD4+ T lymphoblasts [120]. HIV variants derived from monocytes could 
infect both macrophages and CD4+ T lymphoblasts, while viruses derived from 
lymphoblasts showed a sole preference for infecting T lymphoblasts [121]. Based on 
these observations as well as other similar ones, HIV was classified into M-tropic 
(macrophage- or monocyte-tropic) and T-tropic (T-cell-tropic) viruses, indicating that 
HIV viruses could either be dualtropic for macrophages and T cells or have mixed 
populations of M-tropic and T-tropic viruses coexisting simultaneously within the same 
individual [122].  
 
1.3.2 Growth Kinetics 
Another classification, based on growth kinetic properties, was introduced by a 
Swedish research group in 1989 [123]. Viruses derived from asymptomatic patients or 
patients with minor symptoms replicated slowly and inefficiently in PBMC cultures 
and could often not be passaged at all in CD4+ T-cell lines, while viruses from patients 
with severe AIDS replicated rapidly and efficiently both in T cell lines and PBMC 
cultures. Hence, the viruses were classified into slow/low and rapid/high, respectively, 
and it was observed that a shift from one to the other could occur in a patient over time. 
The slow/low viruses were exclusively M-tropic, while the rapid/high were both M- 
and T-tropic, based on the viruses’ abilities to infect indicator monocytoid and T-
lymphoid cell lines, respectively [123].  
 
1.3.3 Syncytium Inducement 
The slow/low and rapid/high viruses also differed from each other by displaying 
different cytopathogenic effects in cell culture [123]. The rapid/high dual T- and M-
tropic viruses caused extensive syncytium formation in MT2 cell lines, which are 
derived from T cells, while the M-tropic slow/low viruses rarely did so. This lead to the 
classification of viruses into non-syncytium inducing (NSI) and syncytium inducing 
(SI), resulting in the MT2 cell culture test being used as a prognostic assay to determine 
the disease stage of the patient [124]. 
 
1.3.4 Coreceptor Use 
That HIV-1 used the CD4 receptor for cell entry was found early on after the discovery 
of the virus [53, 54, 125], but even then it was acknowledged that some other factor 
was necessary to complete the entry process [126]. In 1996, it was established that 
HIV-1 uses chemokine receptors as coreceptors in addition to CD4 to enter cells 
(Figure 8), and these receptors could be either CCR5 [60-62] or CXCR4 [63, 64]. A 
new phenotype classification was consequently introduced in 1998 [118], where viruses 
using CCR5 were proposed to be called R5, while viruses using CXCR4 were to be 
called X4. Dualtropic viruses [127] were denoted R5X4, and later as new HIV-1 
coreceptors were added to the list [127, 128], they received similar abbreviations, such 
as R3 for viruses using the C-C chemokine receptor type 3 (CCR3).  
The new classification based on coreceptor use could more precisely describe the 
biological properties of a viral isolate [118]. R5 viruses would not be syncytium 
inducing (NSI), since MT2 cell lines lack CCR5 receptors, but they would be both M- 
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and T-tropic, since both macrophages and T-cells express CCR5, and most likely 
slow/low. X4 viruses on the other hand would be syncytium inducing (SI) due to the 
expression of CXCR4 on MT2 cell lines, T-tropic, and rapid/high. Dualtropic R5X4 
viruses would combine properties from both R5 and X4, and be SI, M-tropic and T-
tropic, as well as likely rapid/high. 
   
 
Figure 8. HIV-1 binding to the host cell, involving the primary receptor CD4 and the 
coreceptors CCR5 or CXCR4. Adapted with permission from [129]. Illustrator: Taina Litwak.  
 
1.4 HIV-1 ENTRY CORECEPTORS 
The main coreceptors of HIV-1 are considered to be CCR5 and CXCR4, but the virus 
may also utilize other receptors such as CCR1, CCR2b, CCR3, CCR4, CCR8, V28, 
BoB (GPR15), Bonzo (STRL33) and Apj [128, 130-133]. 
 
1.4.1 CCR5 
The natural ligands of chemokine receptors are chemotactic cytokines (chemokines), 
which facilitate the chemotaxis of phagocytic cells and T cells to areas of inflammation. 
The chemokines that naturally bind the CCR5 receptor are the β-chemokines RANTES 
(Regulated on Activation Normal T cell Expressed and Secreted), MIP1α (Macrophage 
inflammatory protein-1α) and MIP1β [134, 135]. RANTES is involved in 
chemoattracting monocytes, memory T cells and eosinophils as well as in the 
inducement of histamine release by basophils [134]. MIP1α and MIP1β both mediate 
macrophage migration, but when it comes to other leukocytes, MIP1α primarily 
mediates migration of B lymphocytes, activated CD8+ T cells, NK cells and 
eosinophils, while MIP1β preferentially mediates migration of CD4+ T cells [136, 
137]. All three chemokines are capable of blocking R5 virus infection in vitro [138], 
but in vivo they can limit replication, but not hinder disease progression [139]. 
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CCR5 is substantially expressed on activated memory CD4+ T cells and GALT, as well 
as on macrophages, monocytes, microglia (resident macrophage type in the central 
nervous system), NK cells, dendritic cells and Langerhans cells (dendritic cells in 
mucosal epithelia), which also express lower levels of CD4, making these cells target 
cells for R5 viruses [140-147], which require both CD4 and CCR5 expression for cell 
entry. 
 
The CCR5 receptor is a member of the G protein-coupled receptor superfamily. It is a 
7-transmembrane protein, composed of four intracellular and three extracellular loops 
joined by hydrophobic membrane spanning domains, as well as an extracellular N-
terminal and a cytoplasmic C-terminal domain [148]. A single potential N-linked 
glycosylation site is present in the third extracellular loop (ECL3) [134], but it is not 
posttranslationally modified [149], likely due to its proximity to the disulfide bridge 
formed between the N-terminal and ECL3. Unlike most other G protein-coupled 
receptors, no potential glycosylation sites are present in the N-terminal [134], which is 
important for ligand binding [148] along with ECL2 [150].  
 
Viruses with the R5 phenotype are generally the first to be present at the start of the 
infection [131, 151-154], and have also been associated with transmission [30, 153-
157]. These variants are mainly T-tropic [154, 155, 157] and require high amounts of 
CD4 on the host cell’s surface [156, 157], as opposed to R5 viruses that develop later 
during the infection that have adapted to entering host cells with fewer CD4 molecules 
on the surface, such as macrophages [153, 158], which play a role in HIV-1’s infection 
of the central nervous system [158, 159].  
 
A deletion of 32 base pairs in the gene coding for the CCR5 receptor, designated as 
CCR5∆32, causes a premature stop codon in ECL2 of CCR5, leading to the retention of 
the mutant CCR5 protein in the endoplasmic reticulum [160-162]. The allelic 
frequency of this mutation is about 10 % in Caucasians [161, 162], and homozygous 
individuals are strongly resistant to HIV infection [160, 161, 163], supporting the 
importance of R5 viruses in transmission [30]. However, homozygosity is not an 
absolute protection against infection [164-166], since a few homozygous individuals 
were inferentially alleged to have been infected with X4 viruses [164-166]. 
Heterozygous individuals are also protected to some extent from infection [161, 162] 
and disease progression [161, 163]. Even though homozygosity for CCR5∆32 does not 
seem to result in any apparent detectable phenotypic consequences (apart from HIV 
infection protection) in the affected individual [160-162], it has been found that 
homozygotes are at an increased risk of symptomatic West Nile virus infection with 
fatal outcome [167]. On the other hand, homozygous individuals are to some extent 
resistant to acquiring non-HIV related non-Hodgkin lymphoma [168].  
 
1.4.2 CXCR4 
The natural ligand of the CXCR4 receptor is SDF-1 (Stromal cell-derived factor 1) 
[169, 170], initially named owing to it being a bone marrow stromal cell derived factor 
that enhances B cell proliferation [171]. It also acts as a chemoattractant to T 
lymphocytes and monocytes, but not neutrophils [172]. SDF-1 is capable of blocking 
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the infection of X4 viruses in vitro [169, 170], but seems not to have an inhibitory role 
in vivo in patients with advanced disease, suggesting that the virus adapts to escape 
antiviral chemokines [151].  
 
The target cells of X4 viruses are primarily naïve CD4+ T cells [140, 141, 173, 174], 
but CXCR4 is also expressed on other leukocytes, including memory CD4+ T cells, 
GALT, Langerhans cells, and NK cells, which represent additional targets [140, 141, 
145, 147, 174, 175]. In general, CXCR4 is expressed at various levels in nearly all 
lymphocyte subsets, as compared to the more restricted CCR5 [174]. Macrophages and 
monocytes also express CXCR4 [176, 177], but it remains hitherto unclear whether or 
not X4 viruses are capable of productively infecting macrophages [178]. 
 
The CXCR4 receptor is also a member of the G protein-coupled receptor superfamily, 
and is hence in many ways structurally similar to CCR5 [179]. Interestingly, the five 
acidic amino acid residues Asp-972.63, Asp-1714.60, Asp-187 (ECL2), Asp-1935.32, and 
Asp-2626.58 in CXCR4 that are found to be important for ligand binding [180, 181], as 
well as infection with HIV [181], are replaced by the uncharged residues Tyr-892.63, 
Gly-1634.60, Ser-179, Gln-1885.32, and Asn-2586.58 in CCR5 [179]. Also, the N-terminal 
of CXCR4 has nine acidic residues as opposed to only three in the N-terminal of CCR5 
[179]. Moreover, CXCR4 contains two potential N-linked glycosylation sites, one in 
the N-terminal and one in ECL2, respectively, that are absent in CCR5 [182].  
 
X4 viruses are believed to evolve from R5 viruses within a patient [126, 153], and 
generally start to appear with disease progression [126, 131, 151-153], accompanied by 
a rapid CD4 count decline [126, 131, 152]. If X4 viruses are the cause or the effect of 
disease progression remains unclear [126, 183]. However, X4 viruses are easier to 
neutralize compared to R5 viruses [183, 184], which could partially explain their 
appearance when the immune system has sufficiently deteriorated [153, 183].  
 
1.4.3 Dual Tropism 
Dualtropic viruses that utilize both CCR5 and CXCR4 represent an intermediate intra-
patient evolutionary state that arises when R5 viruses acquire enough mutations in 
gp120 to allow the broadening and/or switch of coreceptor use [126, 185]. The 
properties of dualtropic viruses vary, depending on whether or not they use CCR5 or 
CXCR4 more efficiently [186, 187], sometimes denoted as Dual-R and Dual-X, 
respectively [186]. Dual-R viruses have a closer resemblance to R5 viruses genetically, 
while the same is true for Dual-X and X4 viruses [186, 187]. The terminology 
dual/mixed (DM) often appears with regard to dualtropic viruses, indicating that it 
cannot be distinguished whether the bulk of viral isolates contains truly dualtropic 
variants or whether a mixture of R5 and X4 and possibly also dualtropic viruses is 
present [183]. 
 
1.4.4 Other Coreceptors 
As mentioned above, HIV-1 can utilize multiple other receptors as coreceptors in vitro 
apart from CCR5 and CXCR4, but their role in vivo is likely marginal [41, 132, 183], 
with the possible exception of CCR3, which may along with CCR5 play an important 
role in the infection of microglia in the central nervous system [128, 144]. CXCR4-
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using viruses in advanced AIDS patients sometimes evolve the ability to use additional 
coreceptors such as V28, CCR8, and Apj [132], but HIV-1 does not normally utilize 
alternative coreceptors in vivo without also being able to use either CCR5 or CXCR4 
[127, 132, 188]. 
 
1.4.5 Glycoprotein 120’s Interaction with Entry Coreceptors 
The gp120 V3 region was found early on to be important in HIV-1 tropism and 
syncytium-inducing capacity [189-194]. In most isolates, it is composed of 35 amino 
acids forming a loop structure with the help of a disulfide bridge created by the cysteine 
residues found at positions 1 and 35. The V3 loop tip consists of the GPG crown, which 
is fairly conserved and forms a β-turn, whereas the flanking regions of the crown are 
variable and together form the two strands of an antiparallel β-sheet [150, 195-197]. 
The crown plays an important role in the interaction of HIV-1 with the ECL2 of CCR5 
[57, 179, 198] and ECL2 and ECL3 of CXCR4 [180, 199], while the N-terminal region 
of CCR5 interacts with the V3 base [41, 179, 198, 200] and the adjoining bridging 
sheet [57, 200].  
 
The evolution from R5 viruses to X4 viruses involves various amino acid substitutions 
[190-193, 201-206], in particular those that confer a change in the net charge, where a 
higher net charge has been associated with CXCR4 use [190, 192, 193, 202, 203, 205, 
206]. Hence, X4 viruses are also more heterogeneous in their V3 loop compared to R5 
viruses [194, 205-207]. Furthermore, basic amino acid residues in positions 11, 24, 25 
and 28 of the V3 loop have been coupled with CXCR4 use [190, 192, 201, 202, 205, 
206]. The basic nature of the protruding V3 loop of X4 viruses has good electrostatic 
compatibility with the acidic residues in the binding pocket of CXCR4 [179-181], 
additionally supporting the importance of high V3 charge for CXCR4 use.  
 
A potential N-linked glycosylation site, N301, is located in the V3 positions 6-8. The 
loss of this site has been associated with a coreceptor switch from CCR5 to CXCR4 
[208-210], as well as with an increased sensitivity to neutralization [210, 211]. 
Moreover, when this site was removed using site-directed mutagenesis in a dualtropic 
isolate, it lost its CCR5-dependent fusion activity entirely, whereas 50 % of the wild-
type CXCR4-dependent fusion activity was retained, emphasizing the importance of 
this glycosylation site for CCR5 use [212].  
 
Other regions of gp120 can also affect coreceptor use [199, 204, 208, 212-216], in 
particular mutations and deletions in V1/V2 [199, 208, 214-216], while mutations in 
the fusion peptide gp41 may have an impact on coreceptor use too [217].  
 
1.4.6 Biological Coreceptor Use Determination 
In order to determine coreceptor use biologically ex vivo, patient-derived HIV-1 
isolates are tested on specific cell lines such as U87 and GHOST, which apart from 
expressing CD4 are also transfected with CCR5, CXCR4, or other coreceptors of 
interest [62, 183, 218]. Another way to determine coreceptor use ex vivo is by infecting 
cell lines expressing both CCR5 and CXCR4 with patient-derived HIV-1 isolates while 
alternately adding coreceptor antagonists such as the CCR5-inhibiting TAK799 and the 
CXCR4-inhibiting AMD3100 [219, 220]. In more recent years, quite a few 
 18 
recombinant phenotypic assays for determining coreceptor use have been developed, 
including the Trofile assay (Monogram Biosciences) [221]. Partial or full-length viral 
env is amplified from patient plasma and used to create pseudoviruses or infectious 
recombinant viruses. These are then tested for entry on indicator cell lines expressing 
CD4 along with either CCR5 or CXCR4. The advantage of these assays is that it is 
possible to distinguish between pure R5, pure X4 and dualtropic/mixed populations 
[183]. Also, the enhanced sensitivity Trofile assay can detect minor X4 populations that 
constitute as little as 0.3 % of the total quasispecies within a patient with 100 % 
sensitivity [222, 223]. 
  
1.4.7 Coreceptor Use and HIV-1 Subtypes 
CXCR4-using variants appear in about half of the AIDS patients infected with subtype 
B [224, 225], but the prevalence in non-B HIV-1 subtypes varies. The subtype most 
closely related to subtype B, HIV-1 subtype D, is also associated with increased 
CXCR4 use [112, 186, 226], while several reports have suggested the same for 
CRF01_AE [227-229]. The acquisition of CXCR4 use seems on the other hand less 
likely in subtype C even at late clinical stages [207, 230-232], perhaps owing to the 
requirement of more mutations for a coreceptor switch [233]. Then again, later studies 
indicate that CXCR4 use in subtype C may not be as low as earlier reported [234-237], 
which could be attributed to an evolving subtype C epidemic [183, 234, 235]. In 
particular, the increase in CXCR4 use among treatment failure patients infected with 
subtype C [234, 236, 237], is intriguing.  
 
1.5 ANTIRETROVIRAL TREATMENT 
Antiretroviral drugs target different steps of HIV-1’s replication cycle (Figure 9), and 
are consequently divided into drug classes based on the step they target.  
 
1.5.1 Drug Classes 
The drug classes that make up the core components of HAART, the triple drug 
combination given to HIV-1 infected patients in order to avoid the emergence of drug 
resistance, are nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside 
reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI). NRTIs target the 
reverse transcription step by imitating natural dNTPs (deoxynucleoside triphosphates) 
leading to their incorporation into viral DNA and thereby prematurely terminating the 
chain, while NNRTIs target the same step by allosterically inhibiting the reverse 
transcriptase enzyme. PIs, as implied by their name, block the maturation of HIV-1 
virions by acting as competitive inhibitors to the protease enzyme. [238, 239] 
 
First-line treatment usually consists of a combination of two NRTIs and one NNRTI or 
one PI, while other drug classes are generally introduced in second- and third-line 
treatments. If patient compliance desists, single mutations are enough to confer 
resistance to NRTIs and NNRTIs [240, 241], while PIs are more forgiving and require 
more mutations for resistance [242].  
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Figure 9. Antiviral drug classes and HIV-1’s replication cycle. The antiviral drug classes are 
boxed in white while host proteins interfering with the viral life cycle are boxed in grey. 
Reproduced with permission from [238]. 
 
Newer drug classes target other steps of the viral replication cycle, such as the 
integration and the entry step. IN strand transfer inhibitors (INSTIs) block the viral 
DNA transfer activity of the integrase enzyme, thereby preventing integration of the 
viral DNA into the host’s genome. Entry inhibitors can be divided into two subclasses: 
fusion inhibitors, which disrupt the six-helix bundle that brings together the viral and 
host membranes and in so doing prevents fusion, and coreceptor inhibitors. [238, 239] 
 
1.5.2 Coreceptor Inhibitors 
Coreceptor inhibitors are meant to block CCR5 or CXCR4, thereby precluding the 
binding of HIV-1. No CXCR4 inhibitor has been licensed for clinical use to date [243]. 
The synthetic small molecule CXCR4 inhibitors AMD3100 and the orally bioavailable 
AMD11070 were quite well tolerated, but did not show an antiviral effect in the form 
of a significant decrease in viral loads in clinical trials, although a reduction of the 
amount of X4 viruses in the patients was seen [244-246], indicating the potential 
usefulness of giving CXCR4 inhibitors in conjunction with CCR5 inhibitors [243, 246]. 
Further clinical development of AMD11070 has however been halted due to potential 
hepatotoxic effects observed in long-term animal studies [246]. 
 
Substantially more CCR5 inhibitors have been in development compared to CXCR4 
inhibitors, but only one, maraviroc (Figure 10), has been licensed by FDA for clinical 
use [243, 247]. The existence of individuals lacking the CCR5 receptor due to the 
CCR5∆32 deletion, but without any significant health impacts, suggested the safety of 
blocking CCR5 for clinical use. At first, modified natural ligands were tested, but 
owing to their poor oral bioavailability, the research focus shifted to generating small-
molecule antagonists instead, which are given the suffix “viroc” in their names 
meaning “viral receptor occupancy” [243]. These antagonists allosterically alter 
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CCR5’s conformation, resulting in the inability of HIV-1 to bind to the coreceptor 
[179, 243]. Some examples of developed CCR5 inhibitors apart from maraviroc are 
vicriviroc, which did not show significant efficacy in phase III clinical trials [248], 
aplaviroc, which was shown to be hepatotoxic in phase III clinical trials [249], and 
cenicriviroc, which is currently being tested in phase IIb clinical trials [243, 250].  
  
1.5.3 Maraviroc 
Figure 10. Schematic overview of how maraviroc blocks the 
entry process of HIV-1. Adapted with permission from [129]. 
Illustrator: Taina Litwak. 
 
Maraviroc (Selzentry®) was approved by FDA for use in 
treatment-experienced adult HIV-1 infected patients in 
combination with other antiretroviral drugs in 2007 [247]. 
The license was extended to include treatment-naive 
patients in 2009 [243].  Maraviroc is administered on a 
twice daily dosing schedule and is well tolerated [129, 
243].  
 
Despite its approval for first-line treatment, maraviroc is 
mainly given as a second-line drug, due to several 
limiting factors. The twice daily dosing regimen prevents the co-formulation of 
maraviroc with other first-line drugs such as Truvada® and Epzicom®, which combine 
several drugs in one tablet administered only once per day. Reducing the amount of 
drugs given to patients daily has a significant impact on compliance, resulting in 
endeavours to limit first-line treatment to one-tablet-a-day dosing schedules. [243] 
 
Another limiting factor is the requirement of an HIV-1 coreceptor use test to be 
performed before administering the drug, since the prior existence of CXCR4-using 
variants in the patient may lead to limited efficacy of the drug as well as drug resistance 
through the selection for these variants [251, 252]. In the U.S., biological determination 
of coreceptor use is recommended to be performed with the expensive and fairly time-
consuming enhanced sensitivity Trofile® assay, which requires a minimum plasma 
HIV-1 RNA level of ≥ 1,000 copies/ml [221, 243, 253]. Genotypic assays, which 
attempt to predict coreceptor use from HIV-1 sequences, are however the preferred 
coreceptor use determining method in Europe, in particular those utilizing the 
Geno2Pheno algorithm with a false-positive rate of 10 % [254], which when tested 
retrospectively on material from clinical trials correlated well with the clinical outcome 
of maraviroc treatment [255].  
 
Apart from drug resistance acquired through the development and/or selection for pre-
existing CXCR4-using viruses [251, 252], resistance to maraviroc can also arise 
through the emergence of HIV-1 R5 variants associated with particular mutations in V3 
that can utilize the new drug-bound CCR5 conformation [243, 256]. Interestingly, such 
variants do however retain full susceptibility to other CCR5-inhibitors [256].  
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1.5.4 Antiretroviral Treatment Program in Botswana 
As mentioned earlier, the national antiretroviral treatment program in Botswana was 
introduced in 2002 [33]. At the time, the standard first-line treatment consisted of two 
NRTIs, zidovudine (AZT) and lamivudine (3TC), together with one NNRTI, either 
nevirapine (NVP) or efavirenz (EFV), while second-line treatment usually consisted of 
two other NRTIs, didanosine (ddI) and stavudine (d4t), and one PI, nelfinavir (NFV) 
[257]. The latest guidelines from 2012, however, recommend the following regimens: 
two NRTIs, tenofovir disoproxil (TDF) and emtricitabine (FTC), together with one 
NNRTI, EFV, often given as one tablet (Atripla®), as first-line treatment (alternatively, 
the Truvada® tablet can be used, which contains the same drugs, but replaces FTC with 
3TC), and two NRTIs, AZT and 3TC, together with one PI combined with a booster, 
lopinavir/ritonavir (LPV/r), as second-line treatment [258]. Drug resistance testing is 
routinely performed only after the patient has failed second-line treatment [258].  
 
1.6 CORECEPTOR USE PREDICTION MODELS  
Coreceptor use prediction models, as the name implies, use patient-derived HIV-1 
gp120 V3 sequences to predict the coreceptor use of the HIV-1 variants harboured 
within a patient.  Most models do not distinguish between dualtropic and X4 variants, 
categorizing them together as CXCR4 users instead.  
 
1.6.1 Simple Rule Algorithms 
Algorithms based on simple rules appeared even before the discovery of HIV-1’s 
coreceptors, and were used to distinguish between slow/low, M-tropic NSI and 
rapid/high, T-tropic SI variants, as they were classified at the time, and have since then 
been inferentially translated to coreceptor use phenotypes.  The most prominent of 
these is the 11/25 rule, which classifies sequences as CXCR4-using if they contain a 
positively charged amino acid (arginine or lysine) in position 11 of the V3 loop and a 
neutral amino acid in position 25, or just a positively charged amino acid in position 25 
[190]. Another simple rule algorithm derived from the observations of high V3 charge 
in CXCR4 use [190, 192, 193, 202, 203, 205, 206], classifies sequences with a total V3 
charge of ≥ 5 as CXCR4-using.  
 
1.6.2 Learning Algorithms 
As the field of bioinformatics evolved, the use of learning algorithms became common 
for predicting coreceptor use. Learning algorithms are machine-learning methods that 
have been fed sequences with known coreceptor use, based on which scores are 
created. These scores represent how similar the tested sequences are to CXCR4-using 
or non-CXCR4-using sequences that were used to create the algorithm. The scores can 
be visualized on a scale where different false positive rate cut-off points may be chosen 
to denote what scores will be used to classify sequences as CXCR4-using. Examples of 
learning algorithms are SVM (support vector machine) [259], PSSM (position specific 
scoring matrix) [260], and Geno2Pheno [coreceptor] [261], which is available with 
different false positive rate cut-offs, where the 10 % is recommended by the European 
Consensus Group on clinical management of HIV-1 tropism testing [254]. 
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1.6.3 Complex Rule Algorithms 
Complex rule algorithms combine a set of rules into a decision tree. Several have 
become available recently that have been developed for specific subtypes. One of them 
is CoRSeqV3-C (Figure 11) [262], which is meant to be tested on subtype C 
sequences. Other examples are algorithms developed for subtype D [263] and 
CRF01_AE [264] by Raymond et al. that are based on 11/25 and net charge rules, as 
well as the mutations of the V3 N-linked glycosylation site. 
 
Figure 11. The decision tree of 
CoRSeqV3-C showing how 
CXCR4-using sequences are 
classified based on specific V3 
amino acids and total charge. 
Reproduced with permission 
from [262]. 
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2 AIMS 
The general aim of this thesis was to investigate amino acid predictors of HIV-1 
coreceptor use in different subtypes and apply the obtained knowledge to antiretroviral 
treatment. 
 
The more specific aims of each paper were: 
 
Paper I: To investigate in HIV-1 groups and subtypes if the occurrence of potential N-
linked glycosylation sites in and around the gp120 V3 loop may be correlated with 
specific coreceptor use, in particular if N301 is associated with CCR5 use, using all 
available sequences from the Los Alamos HIV Sequence database and allowing only 
one sequence per patient. 
 
Paper II: To characterize charged V3 amino acids in R5 and X4 sequences belonging 
to the major HIV-1 subtypes and describe the coreceptor switch from R5 to X4 from 
this perspective, using all available sequences from the Los Alamos HIV Sequence 
database and allowing only one sequence per patient.  
 
Paper III: To investigate if there is an increase in CXCR4-using viruses in HIV-1 
subtype C patients failing antiretroviral treatment in Botswana compared to treatment-
naïve individuals using population sequencing, as well as to further assess the 
coreceptor use of minor HIV-1 quasispecies in treatment-experienced patients using 
single genome sequencing.  
 
Paper IV: To compare the performance of current available coreceptor use prediction 
algorithms in major HIV-1 subtypes from a CCR5 inhibitor treatment perspective, as 
well as to determine if the “analytical” glycan-charge model, based on observations 
from papers I and II, can complement existing prediction algorithms, using all 
available sequences from the Los Alamos Sequence database and allowing one 
sequence per patient per phenotype.  
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 Sequences from the Los Alamos HIV Sequence Database  
(Papers I, II and IV) 
In paper I, the dataset consisted of 176 sequences retrieved from the Los Alamos HIV 
Sequence database. The sequences were from unique patients and spanned the gp120 
V3 loop and flanking regions. The coreceptor use of each sequence was determined 
biologically and among the 176 sequences, 133 used CCR5, 29 used CXCR4 and 14 
were dualtropic. Most of the sequences belonged to HIV-1 group M (n = 171), but 
group O (n = 4) and N (n = 1) sequences were also included. The group M sequences 
included subtypes A (n = 22), B (n = 62), C (n = 28), D (n = 12), G (n = 5) and U (n = 
1), the circulating recombinant forms CRF01_AE (n = 20) and CRF02_AG (n = 11), as 
well as other recombinants, namely AC (n = 4), AD (n = 1), A1DGJ (n = 1), AU (n = 
1), BC (n = 1) and BF1 (n = 2). 
 
In paper II, the primary dataset consisted of 528 sequences retrieved from the Los 
Alamos HIV Sequence database, out of which 482 were R5 and 46 X4 sequences. The 
sequences were from unique patients, had biologically determined coreceptor use, 
spanned the gp120 V3 loop, and belonged to HIV-1 group M subtypes A (n = 48), B (n 
= 231), C (n = 180), D (n = 37) and the circulating recombinant form CRF01_AE (n = 
32). A secondary dataset, which was used only for within phenotype analyses, 
consisted of an additional 12 R5 and 9 X4 sequences, resulting in a total of 494 R5 and 
55 X4 sequences. Thus, in the secondary dataset, one patient could have a maximum of 
two sequences included: 1 R5 and 1 X4.  
 
In paper IV, the dataset consisted of 1,273 sequences retrieved from the Los Alamos 
HIV Sequence database. One sequence per individual per phenotype was included. The 
sequences spanned the gp120 V3 loop and had biologically determined coreceptor use. 
The dataset contained 1,046 R5, 141 R5X4, and 86 X4 sequences belonging to HIV-1 
group M subtypes A (n = 93), B (n = 607), C (n = 352), D (n = 84) and the circulating 
recombinant form CRF01_AE (n = 137).  
 
3.1.2 Patient Samples from Botswana (Paper III) 
In paper III, blood samples were collected from all adult patients experiencing second-
line treatment failure in Botswana’s national antiretroviral treatment (ART) program 
over a two-month period (May to June) in 2006. In all, twenty-four patients were 
identified, and both sexes were represented in the material. The patients were infected 
with HIV-1 subtype C and were on treatment for a minimum of one year (the exact 
duration of treatment was unavailable). Virological failure was determined as two 
consecutive viral load measures above 1,000 RNA copies/mL, which enabled drug 
resistance genotyping. Drug resistance profiles were available for twelve of the 
patients.  
 
   25 
Twenty-six treatment-naïve patients infected with HIV-1 subtype C were selected as 
controls from a previously described cohort with samples collected in 2003 [265], 
rendering it likely that the treatment failure patients were started on treatment at a time 
point similar to the collection date of the treatment-naïve control samples, since the 
national ART program in Botswana was initiated only a year earlier [33, 257]. 
Furthermore, the probability of finding treatment-naïve patients with low CD4 counts 
would be greater in a cohort from an earlier time point, since the national guidelines for 
treatment commencement were different at the time. The inclusion criteria for the 
controls were an available sequence spanning the envelope gp120 V3 loop and a CD4 
count of ≤ 250 cells/µL, which would have made these patients eligible for treatment in 
2006, and hence increased the likelihood of the CD4 counts being similar in the patient 
and control groups.  
 
3.2 METHODS 
3.2.1 Selection of Sequences from the HIV Sequence Database  
(Papers I, II and IV) 
In paper I, the selection tool on the Los Alamos HIV Sequence database website 
(http://www.hiv.lanl.gov/) was used to collect and sort the material. Initially, 1,015 
sequences spanning the gp120 V3 loop, comprising all HIV-1 groups, group M 
subtypes, sub-subtypes and circulating recombinant forms with a reported coreceptor 
use that were available in the database as of October 2004, were retrieved. 
Subsequently, since there were multiple sequences in the dataset belonging to the same 
individuals, one sequence per patient was selected randomly using lottery, without 
regard to the coreceptor use phenotypes present. Sequences lacking a patient identity 
code or listed with coreceptor use phenotypes other than R5, X4 or dualtropic R5X4, 
were discarded.  
 
The selection process in paper II was similar to that of paper I, but differed in some 
aspects. Initially, all V3 sequences with reported exclusive CCR5 or CXCR4 use in 
HIV-1 group M subtypes A, B, C, D, and CRF01_AE as of June 16th 2009 were 
retrieved from the database, resulting in a total of 3,307 sequences. One sequence per 
patient was chosen using random number generators diminishing the number of 
sequences to 724. The original articles were then perused to confirm that the reported 
coreceptor use of the sequences was determined biologically, decreasing the amount of 
sequences further to 482. During this scrutiny, additional sequences were added from 
the original articles that were either not reported to the database at all or were not listed 
in the database’s initial selection, resulting in a total of 528 sequences, which 
constituted the primary dataset. The secondary dataset allowed the use of one sequence 
per patient per phenotype. Consequently, the material was expanded to include 
additional sequences belonging to patients in the primary dataset that had sequences of 
both phenotypes. The additional sequences in the secondary dataset had sequences 
belonging to the other phenotype of these patients that was not selected in the primary 
dataset, resulting in a total of 549 sequences. 
 
The dataset selection process in paper IV was identical to that of paper II, with the 
exception of also including exclusive dualtropic R5X4 sequences, and allowing one 
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sequence per patient per phenotype in the whole material. Initially, 7,878 sequences 
were retrieved, representing all V3 sequences with reported exclusive R5, X4 or 
dualtropic phenotype in HIV-1 group M subtypes A, B, C, D, and CRF01_AE as of 
October 9th 2013. After the completion of the rigorous selection process (Figure 12), 
1,273 sequences remained, derived from 123 original articles.  
 
 
Figure 12. The sequence selection process in paper IV. *If available, 1 R5 and 1 R5X4 or X4 
was allowed per patient. Reproduced from paper IV.  
 
3.2.2 Population Sequencing (Paper III) 
In paper III, population sequencing was performed on the samples obtained from the 
24 patients failing treatment in order to obtain sequences for evaluating coreceptor use. 
DNA was extracted from 200 µL of buffy coat using the QIAamp Blood kit (Qiagen, 
Chatsworth, CA), eluted in 200 µL and stored at – 20ºC until ready for use. Sequences 
corresponding to the HIV-1 gp120 V3 region as well as flanking C2-C3 regions were 
amplified using two rounds of nested PCR consisting of 40 cycles each [266]. The 
primers used in the first round were JA167 and JA170, while JA168 and JA169 were 
used in the second round [267]. 
 
The PCRs were run in tubes and the results were visualized using gel electrophoresis, 
followed by the purification of the positive PCR products using the QIA quick PCR 
purification kit (QIAGEN, GmbH, Hilden, Germany). Ten ng/µL (Nanodrop) of the 
purified PCR product was used in a 20 µL Big Dye terminator 3.1 (Applied 
Biosystems, Foster City, CA) sequencing reaction, followed by the transfer of the tubes 
to Eurofins MWG Operon, Ebersberg, Germany for sequencing.  
 
The sequences were then edited and assembled into overlapping fragments using the 
software program Sequencher (Gene Codes Corporation, Ann Arbor, MI). Each 
sequence was analyzed for ambiguities at the nucleic acid level for the inclusion into 
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phylogenetic trees. Additionally, majority rule was applied to the V3 region at the 
amino acid level for genotypic assay coreceptor use analysis.  
 
Population sequences from the control patients were retrieved from the Los Alamos 
HIV Sequence database with the help of the accession numbers listed in Ndung’u et al. 
[265].  
 
3.2.3 Single Genome Sequencing (Paper III) 
In addition to population sequencing, single genome sequencing was also performed on 
the samples from the 24 patients failing treatment in paper III, in order to further 
assess the coreceptor use of minor HIV-1 quasispecies. The procedure was mostly the 
same as for population sequencing, but with several additional steps and alterations. 
 
A limiting dilution PCR was performed prior to the regular nested PCR in order to 
determine the dilution that would most likely generate PCR products from single 
quasispecies. The limiting dilution PCR was run in four-fold dilutions of the sample 
DNA with four replicas of each dilution, starting at 1:8, in MicroAmp Optical 96-well 
reaction plates (AB Applied Biosystems, Singapore). Based on the Poisson theory of 
random distribution, a yield of approximately a third positive PCR reactions likely 
represents single proviruses [268-270]. Hence, a dilution was estimated from the 
positive PCR products in the limiting dilution PCR that would likely generate ≈ 25 % 
positive reactions. This dilution was then used to run regular PCR, also in MicroAmp 
Optical 96-well reaction plates, in the hope of amplifying single viral genomes.  
 
Finally, a sequence would be regarded as a single V3 genome only if ambiguities were 
completely absent from V3. If no more than one ambiguity was present, the sequence 
would represent two single V3 genomes and both would be included for the coreceptor 
use determination and phylogenetic analysis. Ambiguities in the flanking regions were 
nevertheless allowed, meaning that each molecular clone would be V3 unique, but 
could consist of multiple variants sharing the same V3 nucleotide sequence. Sequences 
that contained more than one ambiguity in V3 were discarded. 
  
3.2.4 Phylogenetic Analysis (Paper III) 
Phylogenetic trees were created in paper III to illustrate that the generated sequences 
belonged to separate patients, as well as to evaluate within patients that harboured both 
R5 and CXCR4-using sequences how the coreceptor use phenotypes were related to 
each other.  
 
All generated sequences were aligned using Clustal X version 1.81 
(www.clustal.org/clustal2/) and manual adjustments to the alignment were then carried 
out in the Bio Edit Sequence Alignment Editor (www.mbio.ncsu.edu/BioEdit/ 
BioEdit.html). Maximum likelihood phylogenetic trees were generated with bootstrap 
values based on 1,000 data set replicates using Phylip version 3.69 (http://evolution. 
genetics.washington.edu/phylip.html), specifically with the “dnaml,” “seqboot,” and 
“consense” programs. Outgroup rooting was utilized on the phylogenetic tree 
containing all patient sequences (Figure 13) using the group O sequence MVP5180 
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with the accession number L20571. Midpoint rooting was utilized on the phylogenetic 
tree where the R5 and CXCR4-using sequences of specific patients were evaluated. 
 
 
Figure 13. Example of phylogenetic analysis, illustrated using the phylogenetic tree of all 
patient sequences in paper III. The curly brackets indicate separate patients. Bootstrap values 
are given in percentages. Reproduced with permission from paper III.  
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3.2.5 V3 Charge and N-Linked Glycan Site Determination (Papers I to IV) 
In papers I-IV, total charge of V3 sequences was calculated. The premises for these 
calculations are that the amino acids lysine (K) and arginine (R) each have a charge of 
+1, aspartic acid (D) and glutamic acid (E) each have a charge of -1, while histidine (H) 
has a charge of +0.1 under physiological conditions.  
 
In papers I, III and IV, potential N-linked glycosylation sites, or sequon motifs, were 
identified in sequences. The sequons were governed by the amino acid order 
asparagine-X-threonine/serine-Y (N-X-S/T-Y) [271], where X can be any amino acid 
except proline (P) in the threonine (T) context [272, 273] and also not tryptophan (W), 
aspartic acid (D), or glutamine (Q) in a serine (S) context [274]. For the Y position, 
only proline would completely hinder the glycan addition through steric hindrance in 
both contexts [272, 273].  
 
3.2.6 Coreceptor Use Phenotype Prediction (Papers III and IV) 
In papers III and IV, available phenotype prediction algorithms were used to evaluate 
the coreceptor use of sequences. The Geno2pheno [coreceptor] learning algorithm 
[261] with a false positive rate cut-off of 10 % (http://coreceptor.bioinf.mpi-
inf.mpg.de/index.php) was used as the primary coreceptor use determination method in 
paper III, since this is the recommended method by the European Consensus Group on 
clinical management of HIV-1 tropism testing [254].  
 
Geno2pheno with different cut-offs was also one of the evaluated methods used in 
paper IV, along with the learning algorithms PSSM (http://indra.mullins.microbiol. 
washington.edu/webpssm/) [260] and SVM (http://genegames.org/wetcat/v3.html) 
[259], and the simple rule algorithms 11/25 [190] and the total charge rule (see section 
“1.6.1 Simple rule algorithms” for more detailed descriptions). Complex rule 
algorithms were also evaluated and consisted of C4.5, C4.5-8-12 and PART (http:// 
genegames.org/wetcat/v3.html) [259], as well as the more recent subtype-specific 
CoRSeqV3-C (Figure 11) [262] and Raymond et al.’s prediction models for subtype D 
[263] and CRF01_AE [264] (see section “1.6.3 Complex rule algorithms” for more 
detailed descriptions).  
 
3.2.7 Statistical Methods (Papers I to IV) 
Various statistical methods were utilized in papers I-IV. In paper I, two-tailed 
Fisher’s exact test was used to compare the significance of the presence or lack of 
specific glycosylation sites in conjunction with CCR5, CXCR4 or dualtropic use, and a 
one-tailed test in the analysis of total net charge between R5 and X4, and R5 and 
dualtropic sequences, respectively.  
 
In paper II, the median test was used to compare the difference in charge between R5 
and X4 strains in different subtypes. Also, the Wilcoxon signed rank test was used to 
compare the impact of positions 11 and 25 versus other positions in charge acquisition 
in the X4 phenotype in each subtype, and the unstructured mixed repeated effect’s 
model was used for the same comparison, but in all subtypes pooled together.  
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In paper III, two-sided Fisher’s exact test was applied when comparing the outcome 
between the treatment-naïve and treatment failure group, using the same method 
(population sequencing), while the two-sided exact sign test was applied when 
comparing different methods (population versus single genome sequencing) within the 
treatment failure group only. Also, two-sided Student’s t-test was applied when 
comparing the genetic distances from the root of the phylogenetic tree between R5 and 
CXCR4-using strains.  
 
In paper IV, sensitivity, specificity, positive predictive values and negative predictive 
values were calculated for all coreceptor use phenotype prediction algorithms from a 
CCR5 inhibitor usage perspective, i.e. sequences were classified into CXCR4-using 
and non-CXCR4-using, with detected CXCR4 use designated as a positive test.  
 
3.2.8 Ethical Considerations (Paper III) 
All patients enrolled in paper III provided informed consent. The study was approved 
by the ethical committee in Botswana with the registration numbers HRU-13/18/1 Vol 
II (5), HRU-13/18/1 Vol VI (37), and PPME-13/18/1 Vol I (89), as well as by the 
regional board of ethical vetting in Stockholm with the registration number 
2008:2007/1496-31/3.  
 
Papers I, II and IV used publically available sequences from the Los Alamos HIV 
Sequence database, and hence did not require ethical approvals.  
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4 RESULTS AND DISCUSSION 
 
4.1 V3 GLYCAN AND CORECEPTOR USE (Paper I) 
The main aim of paper I was to study the occurrence of potential N-linked 
glycosylation sites in and around the gp120 V3 loop in 176 individually unique 
sequences covering the majority of HIV-1 groups, subtypes, and recombinant forms, 
and investigate if any of these glycan sites could be related to coreceptor use, in 
particular N301 to CCR5 use. Eight potential N-linked glycosylation sites were 
examined (Figure 14), but only the fifth site, N301, which is located in the V3 loop, 
showed a correlation with coreceptor use, namely with CCR5 use as compared to 
exclusive CXCR4 use (P = ≤ 4.6 x 10-12).  
 
 
 
Figure 14. Eight potential N-linked glycosylation sites and their frequencies in the studied V3 
sequences. The position of each glycosylation site is underlined on the HXB2R reference 
sequence, and the presented amino acids have the numbering 228-327 in gp160. The bars 
display in percentages in how many sequences each glycan site was present, respectively. The 
filled bars represent R5 sequences, the hatched dualtropic (R5X4), and the empty bars X4 
sequences. The number of present/absent glycosylation motifs is given above each bar. 
Reproduced with permission from paper I. 
 
As can be seen from Figure 14, only 5 out of 133 R5 sequences lacked the V3 
glycosylation motif. Moreover, the particular NNT motif was conserved within the R5 
sequences of the known HIV-1 group M subtypes in all sequences except one 
(120/121; 99.2 %). Interestingly, the 3 group M R5 sequences that lacked the V3 
glycosylation site, had the amino acid motifs TNT, HNT, and NNA, respectively, 
thereby differing only by 1 nucleotide each from the NNT motif.  
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The loss of the V3 glycosylation site had in previous studies been associated with a 
coreceptor use phenotype switch from R5 to X4 [208-210]. The findings in paper I are 
in agreement with previous results, but emphasize the importance of the V3 glycan for 
CCR5 use in HIV-1 group M. A site-directed mutagenesis study targeting the V3 
glycan in a dualtropic isolate likewise emphasized the importance of the V3 glycan for 
CCR5 use, while the effect on CXCR4 use was moderate [212]. Interestingly, when a 
revertant mutant virus acquired changes in the V3 loop resulting in an increase in net 
charge, it regained full use of CXCR4 [212]. Hence, the loss of the glycan in itself may 
not be enough to attain CXCR4 use, since additional changes in the form of the 
acquirement of positively charged amino acids to increase the total V3 charge seem 
necessary [41, 212, 260]. Furthermore, it has been observed that the presence or 
absence of the V3 glycan did not influence the replication ability of X4 viruses in 
permissive cells [275].  
 
Intriguingly, a later structural study [57] of how the CCR5 N-terminal domain interacts 
with HIV-1 gp120, pointed out the importance of Asn302 (the middle amino acid 
position of the V3 glycosylation motif). Asn302 interacts with the sulfotyrosine Tyr14 
on the N-terminal of CCR5, and the modification of a single nitrogen, leading to the 
transformation of Asn302 to Asp302, ablates recognition of CCR5 [57]. A similar 
modification of the nearby Asn300, which is not part of the V3 glycosylation motif, had 
little impact on the interaction with CCR5 [57]. This could explain the conservation of 
the particular NNT motif in the known HIV-1 group M subtypes found in paper I.  
 
Of additional interest is that CCR5 lacks two potential N-linked glycosylation sites, one 
in the N-terminal and one in ECL2, respectively, that are present in CXCR4 [182]. 
Elimination of these glycans in CXCR4 broadens its coreceptor capacity to include 
several R5 strains, without affecting entrance of X4 strains [182].  
 
Moreover, R5 viruses have been found to be less sensitive to neutralizing antibodies 
than co-existing CXCR4 viruses [183, 184]. Hence, yet another observation supporting 
the importance of the V3 glycan for CCR5 use is that the loss of this site results in 
increased sensitivity to neutralization [210, 211]. 
 
Consequently, the correlation of the V3 glycan with CCR5 use obtained in paper I in a 
material collected globally and spanning practically all HIV-1 groups and subtypes, 
strengthens the results obtained by previous and newer studies, by displaying their 
validity in a worldwide and subtype context.  
 
4.2 V3 CHARGE AND CORECEPTOR USE (Papers I and II) 
In paper I, the role of the V3 loop net charge in relation to coreceptor use phenotype 
was also evaluated, and as expected, the net charge of R5 viruses (median charge +3.0) 
was lower than that of X4 (median +5.9) (P = 8.8 x 10-12) and dualtropic viruses 
(median +5.5) (P = 0.002). In addition, a breaking point at a charge of +4.2 was 
established, below which there were no X4 sequences and above which there were only 
10/133 (7.5 %) R5 sequences. Hence, using net charge above +4.2 to distinguish the X4 
phenotype had a sensitivity of a 100 % in the examined material, emphasizing the role 
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of high V3 net charge for X4 viruses established in previous studies [190, 192, 193, 
202, 203, 205, 206].   
 
The main aim of paper II was to characterize the underlying amino acid components 
that result in increased V3 charge in X4 sequences as opposed to R5 sequences in the 
major HIV-1 subtypes, and from this perspective to describe the coreceptor switch from 
R5 to X4. Dualtropic sequences were not included in this material in order to ascertain 
that the observed amino acid properties would pertain to either CCR5 or CXCR4 use.  
 
 
Figure 15. The charged amino acid distributions in the R5 phenotype in different HIV-1 
subtypes. The V3 loop position numbering is indicated at the top. Consensus sequences for 
each subtype derived from the Los Alamos HIV Sequence database are displayed in black. 
When the consensus sequences based on the material differed from that of the database, they 
were additionally displayed in italics. The total charge of each consensus sequence is indicated 
in the charge column. Charged amino acids are bold, the charged amino acid positions 
conserved in all subtypes are shaded, and the subtype-specific ones are boxed, with positively 
charged being red and negatively charged being blue. The proportion of the most common 
amino acid is indicated with a percentage vertically below it, followed by the second most 
common amino acid.  n = number of sequences; * = frequency of the second most common 
amino acid was equal to the first. Reproduced with permission from paper II. 
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Both generally conserved and subtype-specific positively and negatively charged amino 
acid positions were observed in the R5 phenotype (Figure 15). Interestingly, the same 
positions were discerned in the X4 sequences despite their heterogeneity. Nevertheless, 
the X4 sequences had a higher net charge than R5. This was attributed to the 
acquisition of positively charged amino acids other than the subtype-specific and 
generally conserved ones, and the loss of negatively charged amino acids.  
 
The presence of positively charged amino acids at the V3 loop positions 11 and 25 have 
in multiple studies been found to be important markers of the X4 phenotype [190, 192, 
201, 202, 205, 206]. In paper II, the proportion of acquired positively charged amino 
acids at positions 11 and 25 versus other positions that were not subtype-specific or 
generally conserved ones were calculated. For all five subtypes, only 41/161 (25 %) 
acquired positively charged amino acids were at positions 11/25, while 120/161 (75 %) 
were at other positions (P < 0.0001, Wilcoxon signed rank test). Moreover, less than 
half of the X4 sequences (26/55, 47 %) followed the 11/25 rule [190]. Besides, when all 
subtypes were pooled together the impact of other positions that were not subtype-
specific or generally conserved ones on the overall gain in charge was greater than the 
impact of positions 11 and 25 (P = 0.0001, mixed repeated effect’s model). Similarly, 
other positions had an equal or greater impact in individual sequences on overall charge 
increase compared with positions 11 and 25 in 73 % of the total X4 sequences.  
 
Consequently, the observations in paper II of less position-dependent acquisition of 
positive charge provide a simple and plausible explanation for the evolution of X4 from 
R5, decreasing the fundamental role of the 11/25 positions. The importance of the basic 
character of the V3 loop in X4 viruses described in paper II is further strengthened by 
its electrostatic compatibility with the acidic residues in the binding pocket of CXCR4 
observed in mutagenesis and structural studies [180, 181]. 
 
4.3 GLYCAN-CHARGE MODEL (Papers I to IV) 
The V3 sequence properties associated with coreceptor use that were observed in 
papers I and II were used to construct a model for discriminating between different 
coreceptor use phenotypes, referred to as the glycan-charge model (Table 1).  
 
According to the glycan-charge model, R5 sequences are characterized by the presence 
of the V3 glycosylation site N301 and low V3 charge, while X4 sequences are 
characterized by high V3 charge, regardless of the presence of the V3 glycan. 
Consequently, based on these premises the dualtropic sequences should combine the 
R5 property of having the glycan with the X4 property of high V3 charge.  
 
As mentioned above, a charge cut-off of +4.2 below which there were no X4 sequences 
was noted in paper I. This cut-off was used in the glycan-charge model (Table 1a) to 
define the lower charge limit of the dualtropic group, while the higher charge limit was 
defined using the highest V3 charge (+6.1) among the dualtropic sequences in paper I. 
However, within these values, R5 and X4 sequences could be found too. Hence, this 
group is designated as mixed, since the model cannot distinguish between R5, R5X4 
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and X4 when the charge of the V3 sequences falls into this category and the glycan 
motif is concurrently present. 
 
Table 1a. Glycan-charge model based on paper I. 
 Envelope Glycoprotein 120 V3 Region Charge 
 < 4.2 ≥ 4.2 – 6.1 ≤ > 6.1 
Glycan N301 + R5 R5, R5X4, X4 X4 
Glycan N301 – Undetermined X4 X4 
 
Table 1b. Subtype-specific versions of the glycan-charge model based on paper II. 
 Envelope Glycoprotein 120 V3 Region Charge 
Subtype A < 5.3 ≥ 5.3  ≥ 5.3 
Subtype B < 3.3 ≥ 3.3 – 7.1 ≤ > 7.1 
Subtype C < 5.0 ≥ 5.0 – 5.1 ≤ > 5.1 
Subtype D < 5.0 ≥ 5.0 – 6.2 ≤ > 6.2 
CRF01_AE < 4.0 ≥ 4.0 – 5.0 ≤ > 5.0 
Glycan N301 + R5 R5, R5X4, X4 X4 
Glycan N301 – Undetermined X4 X4 
The tables are adapted from paper IV. 
 
The characterization of charged V3 amino acids in different coreceptor use phenotypes 
described in paper II allowed the modification of the glycan-charge model by the 
application of subtype-specific charge cut-offs. However, no dualtropic sequences were 
included in paper II, so the charge cut-offs of the mixed group were defined using the 
range between the X4 sequence with the lowest V3 charge and the R5 sequence with 
the highest V3 charge for each studied subtype and recombinant form. In the subtype A 
sequences there was no overlap between the charge of R5 and X4 sequences, and hence 
the mixed group could not be distinguished from the X4 group by using charge cut-
offs.  
 
When V3 sequences lacking the V3 glycan are encountered with a charge too low to be 
classified as CXCR4-using, they are classified as “undetermined,” since they cannot be 
explained using the glycan-charge model. Such sequences are however rare, and in 
almost all cases their actual biological coreceptor use phenotype is R5. A theoretical 
explanation to the presence of such sequences could be that they were derived from 
plasma samples, where uninfectious or defective viruses also may circulate. Another 
explanation could be that sequences lacking the glycan might still be able to use CCR5 
when the charge is too low for CXCR4 utilization, but that those viruses would 
probably be outcompeted in vivo by R5 viruses containing the V3 glycan, since those 
variants would be better at evading the immune system [210, 211], which could also 
account for why sequences belonging to the “undetermined” category are rarely 
encountered.  
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The glycan-charge model attempts to describe coreceptor use based on biological 
properties. In order for it to be of clinical use, however, it needed to be converted into 
an algorithm form that would categorize sequences into CXCR4-using and non-
CXCR4-using, which is achieved by classifying the mixed group category as CXCR4-
using, even though this entails the risk of at times generating false positive results, 
since the mixed group normally also may contain pure R5. As the glycan-charge model 
is based on biological properties, the algorithm derived from it was classified as an 
“analytical” one. This algorithm was evaluated along with other algorithms for 
coreceptor use prediction in paper IV. A subtype C-specific version of the glycan-
charge model algorithm was also applied on sequences from treatment failure patients 
in paper III.  
 
4.4 CORECEPTOR USE PHENOTYPE DISTRIBUTION IN DIFFERENT 
SUBTYPES (Papers I, II and IV) 
In papers I, II and IV, sequences belonging to different HIV-1 subtypes with known 
biologically determined coreceptor use were retrieved from the Los Alamos HIV 
Sequence database, which contains sequences collected worldwide since the beginning 
of the 1990s. This opened the possibility to study the coreceptor use phenotype 
distribution among the major subtypes, leaving in mind, however, that the perceived 
distribution changes could partially be attributed to the choice of patients being 
included in research studies.  
 
The sequences in paper I were a mix of HIV-1 groups, subtypes, sub-subtypes and 
recombinant forms. Unfortunately, however, within each category there were too few 
sequences for meaningful within-subtype analysis of coreceptor use. There was 
especially a lack of dualtropic and X4 sequences, although it can be noted that subtype 
D had more X4 sequences (n = 9) than R5 (n = 2), which would be in accordance with 
the observations of increased CXCR4 use in subtype D made in other studies [112, 186, 
226].  
 
Table 2. Subtype-specific distributions of the R5 and X4 phenotypes in paper II.  
 
Number of 
sequences 
R5 X4 % R5 
Subtype A 48 45 3 93.8 
Subtype B 231 210 21 90.9 
Subtype C 180 171 9 95.0 
Subtype D 37 31 6 83.8 
CRF01_AE 32 25 7 78.1 
Total 528 482 46 91.3 
The table was adapted with permission from the supplementary material in paper II.  
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In paper II, coreceptor use was studied in the major HIV-1 group M subtypes, 
consisting of subtypes A, B, C, D and the circulating recombinant form CRF01_AE 
(Table 2). Also here, the amount of X4 sequences was low, but subtype C displayed 
nevertheless a significantly higher proportion of the R5 phenotype (P = 0.03, two-tailed 
Fisher’s exact test), while CRF01_AE displayed a significantly higher proportion of the 
X4 phenotype (P = 0.015) compared to the other subtypes included in the study. This is 
in accordance with earlier studies associating subtype C with low CXCR4 use [207, 
230-232], as well as with both later and earlier reports associating CRF01_AE with 
higher CXCR4 use [227-229]. 
 
The same subtypes were studied in paper IV, but a lot more sequences could be 
included due to the increase of available sequences in the Los Alamos HIV Sequence 
database. However, since the criteria of sequence inclusion were one sequence per 
patient per phenotype, no coreceptor use distribution calculations would be valid, since 
there would be an overrepresentation of some individuals. Nevertheless, all subtypes 
had by now more reported R5 sequences than they had dualtropic or X4 sequences, and 
subtype A had an exceedingly low amount of reported X4 sequences (n = 4), which 
could either indicate the smaller amount of studies being conducted on this subtype or 
imply an actual indication of low CXCR4 use in this subtype.  
 
4.5 CORECEPTOR USE IN TREATMENT FAILURE IN SUBTYPE C  
(Paper III) 
Despite the correlation of subtype C with low CXCR4 use observed in paper II and in 
other earlier studies [207, 230-232], there have more recently been quite a few reports 
of increased CXCR4 use in treatment failure patients infected with subtype C [234, 
236, 237]. The main aim of paper III was to investigate if there is an increase in 
CXCR4-using viruses in HIV-1 subtype C patients failing antiretroviral treatment in 
Botswana compared to treatment-naïve individuals using population sequencing and 
genotypic assays. The increase of CXCR4-using sequences in treatment-experienced 
patients, especially in a subtype previously reported to have little CXCR4 use, is of 
special consequence with regard to treatment with CCR5 inhibitors, since the only 
CCR5 inhibitor in clinical use, maraviroc, is mostly used as a salvage therapy drug 
[243].  
 
To assess the coreceptor use phenotypes obtained from population sequencing in the 
treatment-naïve and treatment failure patients, the Geno2pheno algorithm with a 10 % 
false positive rate cut-off was used, which is currently the recommended algorithm for 
genotypic assays according to the European Consensus Group on clinical management 
of HIV-1 tropism testing [254]. In addition, the glycan-charge algorithm adjusted for 
subtype C based on papers I and II, was also used for phenotype prediction.  
 
Of the 26 population sequences belonging to the treatment-naïve patients, 2 were 
predicted to be from viruses able to use CXCR4 by the Geno2pheno method, while the 
glycan-charge algorithm predicted all 26 to be R5 (Table 3). Among the 24 population 
sequences belonging to the treatment-experienced patients, 8 were predicted to be from 
CXCR4-using viruses by the Geno2Pheno method, while the glycan-charge algorithm 
predicted 5 sequences to be potential CXCR4 users (Table 3). The seemingly higher 
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proportion of CXCR4-using viruses in the treated individuals’ populations (8/24, 
33.3%) versus the treatment-naïve individuals’ populations (2/26, 7.7 %) as predicted 
by Geno2pheno was statistically significant (P = 0.03). This was also the case for the 
predictions made using the glycan-charge algorithm: 5/24 (20.8 %) treated CXCR4 
users versus 0/26 (9%) treatment-naïve users (P = 0.02). 
 
Table 3. Prevalence of potential CXCR4-using HIV-1 subtype C sequences in treatment-naïve 
and treatment failure patients using the Geno2pheno and glycan-charge algorithms, 
respectively, for coreceptor use phenotype prediction.  
 
*The mixed group is regarded as CXCR4-using. †Two-tailed Fisher’s exact test. ‡Two-tailed 
exact sign test. European recom. cut-off = recommendations from the European Consensus 
Group on clinical management of HIV-1 tropism testing (10 % false-positive rate). Adapted 
with permission from paper III. 
 
Single genome sequencing was applied in an attempt to identify CXCR4 use in minor 
HIV-1 quasispecies in the treatment-experienced patients that may have not been 
detected using population sequencing. Two more patients were found to harbour 
CXCR4-using viruses using this sequencing method and the Geno2pheno algorithm 
compared with population sequencing results with the same algorithm, while 
correspondingly 11 more individuals were found to harbour CXCR4-using viruses 
using the glycan-charge algorithm (Table 3).  
 
Consequently, a statistically significant increased frequency of CXCR4-using viruses 
was detected by genotypic tropism testing on population sequences in HIV-1 subtype C 
infected patients failing antiretroviral treatment compared with treatment-naïve 
patients, suggesting that CCR5 inhibitors may be less suitable as drugs in treatment-
experienced as opposed to treatment-naïve patients. Additionally, an even higher 
frequency of CXCR4-using viruses was detected using single genome sequencing in 
treatment-experienced patients.  
 
An increase in CXCR4 use in treatment failure patients has previously been ascribed to 
factors such as suboptimal treatment [234], specific drug resistance mutations [234, 
276], or low CD4 counts [234, 236, 237]. However, in Botswana the treatment 
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adherence rates have been good [257], and no statistically significant correlation could 
be observed in paper III between coreceptor use and specific drug resistance mutations 
or drug classes, although it should be noted that drug resistance profiles were available 
for only half of the patients. With regard to low CD4 counts, an attempt was made to 
minimize this bias by including control patients from an earlier cohort with CD4 counts 
that would have warranted treatment according to the current national guidelines, and 
hence likely matched the CD4 counts of the treatment-experienced patients. However, 
consequently since the collection date was later for the treatment-experienced patients, 
the observed increased CXCR4 use could be the result of the evolving subtype C 
epidemic [183, 234, 235].  
 
Another large recent study in Botswana, which focused on subtype C infected 
treatment-naïve women with low CD4 counts, showed that the prevalence of CXCR4-
using virus was still low in this group [277] compared to prevalence in subtype B 
infected individuals. These results in conjunction with those obtained in paper III 
further support the usefulness of maraviroc as a first-line drug among subtype C 
patients, at least in Botswana.  
 
A limitation of paper III was that patients failing first-line ART could not be included, 
since according to the national treatment guidelines, only patients failing second-line 
treatment are eligible for drug resistance genotyping. As the source of samples was the 
national drug resistance genotyping laboratory, only samples where genotyping had 
been performed for clinical use could consequently be accessed. Hence, the treatment-
experienced patients included in paper III may have had more opportunity to acquire 
multiple drug resistance mutations, which has been linked to CXCR4 use [278], 
compared to treatment-experienced patients who fail first-line treatment.  
 
Another limitation of paper III was the unavailability of material for creating single 
genomes from the treatment-naïve patients, since only population sequencing data from 
2003 were available for the treatment-naïve patients and not their DNA samples. For 
this reason, a comparison between the treatment-naïve and the treatment-experienced 
patients could only be performed on a population sequencing level, ruling out the 
possibility to assess how the potential existence of minor CXCR4-using quasispecies in 
the treatment-naïve group would affect the comparison with the treatment-experienced 
group, where it was shown that more CXCR4 users were detected with single genome 
sequencing. On the other hand, the clinical impact of small proportions of CXCR4-
using virus among a patient’s population of viruses is not known. In paper III, the 
potential CXCR4-using strains in a single individual’s viral population could be 
detected if they represented at least 7 % of the total quasispecies. If even smaller 
proportions of CXCR4 use in a patient’s circulating population of viruses are of clinical 
importance, more sensitive methods would need to be used, such as pyrosequencing 
[279, 280], which however are more expensive and labour intensive, and hence more 
difficult to use in resource-limited settings.  
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4.6 CORECEPTOR USE PREDICTION MODELS AND CCR5 INHIBITOR 
TREATMENT (Papers III and IV) 
In paper III, two different coreceptor use prediction models were used, namely the 
recommended Geno2pheno method and the glycan-charge algorithm adjusted for 
subtype C based on papers I and II. The predictions made by both algorithms were 
plausible even when they did not overlap, as demonstrated using phylogenetic analysis 
methods, implying that the glycan-charge model adjusted for subtype C might have 
potential for further development for clinical use purposes.  
 
Since the introduction of CCR5 inhibitors in ART regimens, accurate coreceptor use 
prediction models for utilization in genotypic assays, in particular those that take into 
consideration subtype variations, have been actively sought after, since biological 
determination of coreceptor use is time-consuming and expensive, and hence acts as a 
limitation to the accessibility of CCR5 inhibitors. The main aim of paper IV was to 
compare the performance of current available coreceptor use prediction algorithms in 
major HIV-1 subtypes from a CCR5 inhibitor treatment perspective. The collected 
testing material in paper IV was uniquely suited for the purpose of testing these 
algorithms due to several aspects. It encompassed patient-derived sequences gathered 
globally that had been accumulated over roughly the latest 15 years of the epidemic up 
until present day. Sequences from even earlier time points were not included, since they 
were not classified according to the coreceptor use phenotype classification, which was 
not implemented until 1996 [118], thereby reducing possible misclassifications of 
coreceptor use due to inference from previous phenotype classifications. Furthermore, 
the material underwent a uniquely rigorous scrutiny with regard to the verification of 
the biological determination of the coreceptor use phenotypes, which was based on the 
original article sources as opposed to the information provided by the database due to 
the database information often being incomplete and at times incorrect.  
 
The 24 evaluated algorithms included simple rule algorithms, learning rule algorithms, 
complex rule algorithms, and the “analytical” glycan-charge algorithm based on papers 
I and II and applied in paper III. Some of the algorithms were subtype-specific and 
were hence only evaluated on sequences from their respective subtype.  
 
Learning algorithms generally performed well at predicting coreceptor use phenotypes 
in all studied subtypes. The algorithm that performed best on the whole material was 
the learning algorithm Geno2pheno (G2P): 2.5 % (false positive rate cut-off) with 
specificity and negative predictive value at 94 % or above, positive predictive value at 
84 %, and sensitivity at 77 %, closely followed by G2P: 5 %, which performed 
similarly, but had higher sensitivity at 77 %, but lower positive predictive value at 70 
%. The clinically recommended G2P: 10 % performed well as well, with sensitivity and 
specificity above 80 % and negative predictive value at 96 %, but had a low positive 
predictive value at 55 %, indicating a trade-off for higher sensitivity by allowing more 
false positives.  
 
The rule algorithms, both the simple and complex, had consistently high specificities, 
ranging from 92 to 99 % in all subtypes, but were usually not very sensitive. An 
exception to that were the more recent subtype-specific complex algorithms, where the 
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subtype C specific CorSeqV3-C [262] outperformed all the studied methods with all 
values above 90 %, but as it was subtype-specific, its values were only applicable for 
that subtype. Similarly, the subtype-specific complex algorithms created by Raymond 
et al. for subtype D [263] and CRF01_AE [264] also had the best sensitivities among 
the remaining rule algorithms, with 90 % and 67 %, respectively.  
 
Sensitivities were generally low for all algorithms tested on subtype A, ranging from 33 
to 75 %, perhaps implying that subtype A X4 sequences may be more homogeneous 
and hence more similar to subtype A R5 sequences, rendering them more difficult to 
distinguish, which would increase the risk of generating false negatives. In contrast to 
this, the algorithms tested on subtype D were not very specific, since 9 out of 18 tested 
methods had values below 75 %, possibly implying that subtype D R5 sequences may 
be more heterogeneous and hence more similar to subtype D X4 sequences, making 
them more difficult to distinguish as well, which would increase the risk of generating 
false positives. A plausible explanation for these observations could be that viruses of 
different subtypes need to travel different evolutionary distances for their R5 viruses to 
evolve CXCR4 use [41]. The observations made in paper IV regarding subtypes A and 
D are of special interest, since these subtypes co-exist in the same regions of sub-
Saharan Africa, but subtype D has been associated with a larger proportion of CXCR4-
using viruses [112, 186, 226] and a faster disease progression compared to subtype A 
[108-111]. Of additional interest was that none of the tested algorithms performed 
particularly well on subtype B even though most of them were designed using subtype 
B sequences. A similar trend was noted for subtype D sequences, which are closely 
related to subtype B sequences [2, 281] and display quite a high level of heterogeneity.  
 
The “analytical” glycan-charge algorithm had generally an average performance on all 
subtypes, excepting perhaps subtype C where it performed quite well. The glycan-
charge model is well suited for descriptive and explanatory purposes of the biological 
properties of coreceptor use, but needs to be developed further in order to be useful as 
an algorithm designed for clinical use. The glycan-charge model had particular 
difficulties with classifying correctly the dualtropic sequences, which in fact was 
difficult for all of the evaluated algorithms. One possible reason for this was that some 
of the sequences that were denoted as dualtropic actually could be R5 or X4, since they 
might have been derived from a dual/mixed population. Another possible reason could 
be that some of the dualtropic sequences utilized CCR5 or CXCR4 more efficiently 
than the other coreceptor [186, 245], and hence the sequences would look more R5- or 
X4-like, respectively [186]. It now remains to elucidate the biological role of these 
dualtropics. Perhaps it is not crucial for prediction algorithms in clinical use to detect 
R5-like dualtropic sequences, since it is possible that their impact on drug resistance is 
negligible due to an inefficient use of CXCR4, and that maybe only the dualtropic 
sequences that are X4-like will not be blocked by CCR5 inhibitors. This is inferred 
from that X4-like dualtropic sequences were efficiently inhibited by CXCR4 inhibitors, 
while R5-like dualtropic sequences were not [245]. Hence, studies like paper II, where 
the amino acid predictors of coreceptor use are studied in pure R5 and X4 sequences, 
are crucial for the validation of the actual properties that pertain to CCR5 and CXCR4 
use, respectively, that can then be applied to how dualtropic sequences are classified. 
Moreover, some dualtropic sequences have identical V3 loops with R5 sequences 
[186], indicating the potential role of regions outside of V3 in coreceptor use. How 
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important these regions are for the ability to acquire efficient CXCR4 use needs to 
however be evaluated further.  
 
4.7 LIMITATIONS OF DATABASE MATERIAL (Papers I, II and IV) 
The Los Alamos HIV Sequence database, from which material for papers I, II and IV 
was retrieved, is a tremendous and unique asset for the HIV-1 research field, since it 
enables large amounts of sequences representing the whole pandemic to be studied. 
However, it has a number of limitations, in particular regarding the reporting of 
coreceptor use, that need to be kept in mind during the retrieval and subsequent 
analysis of the database sequences.  
 
There is no current golden standard regarding the biological determination of 
coreceptor use, which may lead to quality variations of the collected sequences, with 
there not always being a perfect correlation between given sequence and alleged 
coreceptor use phenotype, exemplified by sequences derived from plasma although the 
coreceptor use determination was performed using viral isolates in entry assays. Also, 
the coreceptor use of many older sequences is inferred from previous classifications.  
 
There is a skewed distribution in the database with regard to R5 and X4 sequences, 
with there being a lot fewer dualtropic and X4 sequences submitted. The low amount of 
CXCR4-using sequences will influence the ability to reach statistical significance of 
findings when R5 and X4 sequences are compared with each other, and the validity of 
any observations made in R5 sequences will inevitably weigh greater, since they will be 
based on more sequences.  
 
Even though the sequences by and large are representative of the pandemic, there may 
be a bias in the subtype and phenotype distributions regard to which patients and in 
which countries most studies are conducted.  
 
In addition to all of the above, the information accompanying the sequences in the 
database may be incomplete or sometimes even incorrect. For instance, sequences 
listed as dualtropic are often actually dual/mixed, and some sequences with reported 
coreceptor use were in fact never evaluated for that. Consequently, it is of great 
importance that the information given in the database is verified with the original 
articles, like was done in papers II and IV, during the selection and retrieval of 
sequences from the database for analysis.   
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
To study the evolution of the coreceptor switch from R5 to X4 is important, since it 
may have clinical implications. It remains unknown if the acquirement of CXCR4 use 
by HIV-1 variants within a patient is the cause or the result of disease progression. 
Regardless, more knowledge is needed concerning the amino acid predictors of 
coreceptor use in HIV-1 sequences, since this could provide information about disease 
stage as well as be applied to antiretroviral treatment, in particular to the clinical use of 
CCR5 inhibitors.  
 
The findings in papers I and II support and strengthen current knowledge regarding 
the role of the V3 glycan and charge in coreceptor use, as well as demonstrate the 
validity of this knowledge in a global and subtype context. This information can help 
improve as well as create new coreceptor use prediction algorithms utilized in 
genotypic tropism testing prior to the administration of CCR5 inhibitors, thereby 
improving their accessibility in resource-limited settings. The analytic approach of the 
glycan-charge coreceptor prediction model, based on the observations in papers I and 
II, that is firmly rooted in the biological properties of coreceptor use, can be of 
particular use in the improvement of coreceptor use prediction algorithms, since it 
elucidates the truly important components determining coreceptor use. Hence, elements 
derived from the glycan-charge model, such as the importance of the V3 glycan for 
CCR5 use, can be incorporated into complex rule prediction algorithms where they 
would weigh more heavily in the prediction process compared to other rules not 
derived from biological property observations.  
 
The varying distribution of HIV-1 subtypes worldwide and their possible differences in 
disease progression and coreceptor use emphasize the need to develop coreceptor use 
prediction algorithms that are subtype-specific. Moreover, subtype-specific prediction 
algorithms were shown in paper IV to perform the best with regard to predicting 
coreceptor use from a CCR5 inhibitor treatment perspective. As new coreceptor 
prediction algorithms frequently emerge and methods to determine biological 
coreceptor use phenotype become more and more standardized, the continual 
evaluation of the performance of available algorithms, as was done in paper IV, 
becomes imperative. 
 
The findings in paper III of increased CXCR4 use in treatment failure patients infected 
with subtype C compared with treatment-naïve patients could likewise have significant 
clinical implications, since these findings help to elucidate which patient group might 
be a poorer candidate for treatment with CCR5 inhibitors. Future studies are warranted 
that compare treatment outcomes and drug resistance development in patients treated 
with CCR5 inhibitors within salvage therapy regimens compared to within first-line 
treatment regimens. These studies would be able to address the pressing question 
regarding what proportions of CXCR4-using variants and which particular CXCR4-
using variants within a patient are of actual clinical importance, which could help in the 
choice of sequence generating method as well as of phenotype prediction algorithm. 
 44 
6 ACKNOWLEDGEMENTS 
 
I would like to express my sincerest gratitude to the people that have aided and 
supported me during this long and tedious but rewarding journey we all call PhD 
education: 
 
First of all, none of this would be possible without my late main supervisor, Anneka 
Ehrnst. Anneka, you were not only a great source of inspiration to me ever since I first 
entered your lab at the age of 17, you were an enthusiastic teacher and a generous 
person, who invested so much time in your PhD students, but above all, to me, you 
were my dearest friend. Words cannot express how much I miss you, but in my heart 
and in my mind you were guiding me all the way up until this moment, even though 
you are no longer with us. Thank you for preparing me so well and for the wonderful 
years in science that I got to spend working with you.  
 
I am also infinitely grateful to my current main supervisor, Gunilla Karlsson 
Hedestam. Thank you, Nilla for welcoming me into your wonderful group and giving 
me such free reigns to complete all of my work. You have inspired and guided me more 
than you know, and I have really learned a lot from you during this past year. I look 
forward to our future collaborations together.  
 
Peter Clevestig, my co-supervisor, you have been there from the very start to the end. I 
learned my very first lab skills from you, just pipetting with water, and I’ll never forget 
the highlights of my early scientific days, which were composed of solving crossword 
puzzles with you during our coffee breaks.  
 
My former lab group: 
 
Rozina Caridha, my dear, dear friend. My lab life changed forever when you joined 
our group. Thank you for the immense support over the years through the highs and 
lows, and for being such an unselfish, wonderful being.  
 
Sven Grützmeier, for all the inspiring clinical discussions over the years, which has 
helped form me in my role as a doctor. Thank you also for all the lovely dinners we’ve 
had with our little group at your place. It has really helped us keep our identity and 
remember our dear Anneka. 
 
Simani Gaseitsiwe, for the wonderful collaboration on paper III, and for teaching me 
about the Botswanian culture.  
 
My current lab group: 
Marjon, Gabriel, Monika, Ganesh, Martina, Paola, Marc, Faezzah, Saskia, Flavio, 
Anna, and Gerry. Thank you for making me feel so welcome. You are all such great 
people and I’m glad I got to spend so much time with you this year.  
 
   45 
Ingemar Ernberg, thank you for being such an inspirational and enthusiastic group 
leader. Your advice over the years have been invaluable. 
Ingemar Ernberg’s group:  I’ve really enjoyed all the Friday coffee breaks with you! 
Thank you for helping me out during the times when I shared a lab with you.  
 
To my mentor: 
Hanna Brauner, you have been superb at supporting me over the years! 
 
To my half-time committee members:  
Jan Albert, Patrik Medstrand, and Annelie Tjernlund, for giving me the right 
guidance and feedback that has helped me reach the point where I am now. 
 
Special thanks to Francesca Chiodi and The-Hung Bui, for always showing an 
interest and being supportive. 
 
To my students in my former group:  
Johanna, Desmond, and Marcus – thank you for helping me learn to teach and for 
being such enthusiastic learners yourselves.  
 
To all of my co-authors not mentioned above:  
Max Essex, Madisa Mine, Thomas Leitner, Ulrik Fried, Gaseene Sebetso, 
Thongbotho Mphoyakgosi, and Thabo Diphoko. Thank you for all your valuable 
comments and input in our joint collaborations. 
 
To all the kind MTC people that have made my PhD years so much more fun: 
Maryam, Chaniya, Maria-Lisa, Lech, Jola, Stefano, Qin, Frank, Tatiana, and 
many many more – you know who you are! 
 
To all of my friends with special thanks to: 
Camilla, for teaching me how to use ReadCube and letting me share and vent when 
times have been low in science. 
Cecilia, for all the constant pep talks and the lovely pep card that helped me through 
the last half year of my PhD education. 
Also thanks to Vendela, Eyvind, Olga and Tomas, Shermineh, Nastya, Robert, 
Jonathan, Hannes, Anders and Theresia, Sofia and Hannes, Malin and Henrik, 
Resha, Fredrik, Piotr, Katri and Oleg and their girls, Irina and Hossein with their 
boys, Elena Grigorjevna, Lena and Patrik with their girls, Pia and Svante, Valera 
and Lilja, and everyone else who’s been there for me! 
 
And then of course to my wonderful family:  
 
My grandparents Larissa and Slava, who have provided with inspiration, food, support 
and love all throughout these times. 
 
To my parents-in-law, Frans and Eva, as well as my brother-in-law, David, for 
welcoming me into their family and always being ready to help out when computer 
problems were nigh.  
 
 46 
To my dear cousins, Shakil and Sheila, Shohag and Prova, Moon, Mehrab and of 
course the unforgettable darlings Nusaib and Samrina. Thank your for believing in me 
and always being there.  
 
To my aunt Larisa, who always has the right word to say when I’m feeling low. 
 
To my mother Svetlana, who has sat up through long nights in solidarity when I’ve 
been working hard, and has always pushed me to be better, which I’m very thankful 
for. 
 
To my father Aladdin, my big scientific inspiration. When I hear the word scientist, I 
always think of you first, because you are the complete personification of what a 
scientist should be! Thank you for reviewing every part of this thesis and supporting me 
so much! I’m so proud to be walking in your footsteps. 
 
To my beloved little brother Alec, you are the pride and joy of my life!! Thank you for 
helping me with the formatting of this thesis. You are truly the best brother one can 
have. 
 
And last but not least, to the love of my life, Daniel, my husband. You’ve truly been 
there for me all the way from the very beginning, and you understand me like no one 
else. I’m immensely grateful for the life that we share together.  
 
 
   47 
7 REFERENCES 
 
1. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring 
Harb Perspect Med. Sep 2011;1(1):a006841. 
2. Peeters M, Jung M, Ayouba A. The origin and molecular epidemiology of HIV. 
Expert Rev Anti Infect Ther. Sep 2013;11(9):885-896. 
3. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic 
and nonpandemic HIV-1. Science. Jul 28 2006;313(5786):523-526. 
4. Van Heuverswyn F, Li Y, Neel C, et al. Human immunodeficiency viruses: SIV 
infection in wild gorillas. Nature. Nov 9 2006;444(7116):164. 
5. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. 
Trends Microbiol. Dec 2008;16(12):588-595. 
6. Gao F, Yue L, White AT, et al. Human infection by genetically diverse 
SIVSM-related HIV-2 in west Africa. Nature. Aug 6 1992;358(6386):495-499. 
7. Chen Z, Telfier P, Gettie A, et al. Genetic characterization of new West African 
simian immunodeficiency virus SIVsm: geographic clustering of household-
derived SIV strains with human immunodeficiency virus type 2 subtypes and 
genetically diverse viruses from a single feral sooty mangabey troop. J Virol. 
Jun 1996;70(6):3617-3627. 
8. Peeters M, Courgnaud V, Abela B, et al. Risk to human health from a plethora 
of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis. 
May 2002;8(5):451-457. 
9. Locatelli S, Peeters M. Cross-species transmission of simian retroviruses: how 
and why they could lead to the emergence of new diseases in the human 
population. AIDS. Mar 27 2012;26(6):659-673. 
10. UNAIDS. 2013 Global Report Epidemiology Slides. 2013. 
11. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 
pandemic strains. Science. Jun 9 2000;288(5472):1789-1796. 
12. Worobey M, Gemmel M, Teuwen DE, et al. Direct evidence of extensive 
diversity of HIV-1 in Kinshasa by 1960. Nature. Oct 2 2008;455(7213):661-
664. 
13. Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD. An African 
HIV-1 sequence from 1959 and implications for the origin of the epidemic. 
Nature. Feb 5 1998;391(6667):594-597. 
14. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New 
York City and California. MMWR Morb Mortal Wkly Rep. Jul 3 
1981;30(25):305-308. 
15. Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol. 
Nov 2007;37 Suppl 1:S94-102. 
16. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic 
retrovirus from a patient at risk for acquired immune deficiency syndrome 
(AIDS). Science. May 20 1983;220(4599):868-871. 
17. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of 
cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for 
AIDS. Science. May 4 1984;224(4648):500-503. 
18. Coffin J, Haase A, Levy JA, et al. What to call the AIDS virus? Nature. May 1-
7 1986;321(6065):10. 
19. Safai B, Sarngadharan MG, Groopman JE, et al. Seroepidemiological studies of 
human T-lymphotropic retrovirus type III in acquired immunodeficiency 
syndrome. Lancet. Jun 30 1984;1(8392):1438-1440. 
 48 
20. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC. Antibodies 
reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of 
patients with AIDS. Science. May 4 1984;224(4648):506-508. 
21. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human 
immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. 
AIDS Clinical Trials Group. N Engl J Med. Apr 18 1996;334(16):1011-1017. 
22. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and 
didanosine compared with zidovudine and didanosine in patients with HIV-1 
infection. A randomized, double-blind, placebo-controlled trial. National 
Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group 
Protocol 241 Investigators. Ann Intern Med. Jun 15 1996;124(12):1019-1030. 
23. Staszewski S, Miller V, Rehmet S, et al. Virological and immunological 
analysis of a triple combination pilot study with loviride, lamivudine and 
zidovudine in HIV-1-infected patients. AIDS. May 1996;10(5):F1-7. 
24. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and 
efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. Jan 
19 2006;354(3):251-260. 
25. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-
drug regimens as initial therapy for HIV-1 infection. N Engl J Med. Dec 11 
2003;349(24):2293-2303. 
26. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line 
antiretroviral therapy with regimens including nevirapine, efavirenz, or both 
drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN 
Study. Lancet. Apr 17 2004;363(9417):1253-1263. 
27. Life expectancy of individuals on combination antiretroviral therapy in high-
income countries: a collaborative analysis of 14 cohort studies. Lancet. Jul 26 
2008;372(9635):293-299. 
28. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients 
in the first year of antiretroviral therapy: comparison between low-income and 
high-income countries. Lancet. Mar 11 2006;367(9513):817-824. 
29. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. Oct 
2 2008;455(7213):613-619. 
30. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med. Nov 
2012;2(11). 
31. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America--forgotten but not 
gone. N Engl J Med. Mar 18 2010;362(11):967-970. 
32. Crepaz N, Marks G. Towards an understanding of sexual risk behavior in 
people living with HIV: a review of social, psychological, and medical findings. 
AIDS. Jan 25 2002;16(2):135-149. 
33. National AIDS Coordinating Agency. Botswana 2012 Global AIDS Response 
Report. 2012. <http://www.unaids.org/en/dataanalysis/knowyourresponse/ 
countryprogressreports/2012countries/ce_BW_Narrative_Report[1].pdf> 
34. Kandala NB, Campbell EK, Rakgoasi SD, Madi-Segwagwe BC, Fako TT. The 
geography of HIV/AIDS prevalence rates in Botswana. HIV AIDS (Auckl). 
2012;4:95-102. 
35. Briggs JA, Wilk T, Welker R, Krausslich HG, Fuller SD. Structural 
organization of authentic, mature HIV-1 virions and cores. EMBO J. Apr 1 
2003;22(7):1707-1715. 
36. Meerloo T, Sheikh MA, Bloem AC, et al. Host cell membrane proteins on 
human immunodeficiency virus type 1 after in vitro infection of H9 cells and 
blood mononuclear cells. An immuno-electron microscopic study. J Gen Virol. 
Jan 1993;74 ( Pt 1):129-135. 
   49 
37. Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human 
immunodeficiency virus infectivity and sensitivity to neutralization. J Virol. Jun 
1997;71(6):4847-4851. 
38. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev 
Biochem. 1998;67:1-25. 
39. Robinson HL. New hope for an AIDS vaccine. Nat Rev Immunol. Apr 
2002;2(4):239-250. 
40. Hearps AC, Jans DA. Regulating the functions of the HIV-1 matrix protein. 
AIDS Res Hum Retroviruses. Mar 2007;23(3):341-346. 
41. Arrildt KT, Joseph SB, Swanstrom R. The HIV-1 env protein: a coat of many 
colors. Curr HIV/AIDS Rep. Mar 2012;9(1):52-63. 
42. Fackler OT, Baur AS. Live and let die: Nef functions beyond HIV replication. 
Immunity. Apr 2002;16(4):493-497. 
43. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing 
enzyme APOBEC3G and induces its degradation. Nat Med. Nov 
2003;9(11):1398-1403. 
44. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is 
antagonized by HIV-1 Vpu. Nature. Jan 24 2008;451(7177):425-430. 
45. Strebel K. HIV accessory proteins versus host restriction factors. Curr Opin 
Virol. Dec 2013;3(6):692-699. 
46. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences 
of HIV evolution. Nat Rev Genet. Jan 2004;5(1):52-61. 
47. Coffin J, Swanstrom R. HIV pathogenesis: dynamics and genetics of viral 
populations and infected cells. Cold Spring Harb Perspect Med. Jan 
2013;3(1):a012526. 
48. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. 
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. Jul 
11 1986;233(4760):215-219. 
49. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in 
AIDS: central nervous system HIV-1 infection and AIDS dementia complex. 
Science. Feb 5 1988;239(4840):586-592. 
50. Watkins BA, Dorn HH, Kelly WB, et al. Specific tropism of HIV-1 for 
microglial cells in primary human brain cultures. Science. Aug 3 
1990;249(4968):549-553. 
51. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of 
freshly isolated blood myeloid and plasmacytoid dendritic cells in patients 
infected with HIV-1. Blood. Jun 1 2003;101(11):4505-4511. 
52. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring 
Harb Perspect Med. 2012;2(8). 
53. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. 
The T4 gene encodes the AIDS virus receptor and is expressed in the immune 
system and the brain. Cell. Nov 7 1986;47(3):333-348. 
54. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK. 
Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral 
protein and the T4 molecule. Science. Jan 24 1986;231(4736):382-385. 
55. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 
gp120 glycoproteins with the chemokine receptor CCR-5. Nature. Nov 14 
1996;384(6605):179-183. 
56. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive 
interactions between HIV-1 and its co-receptor CCR-5. Nature. Nov 14 
1996;384(6605):184-187. 
 50 
57. Huang CC, Lam SN, Acharya P, et al. Structures of the CCR5 N terminus and 
of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science. Sep 28 
2007;317(5846):1930-1934. 
58. Reeves JD, Miamidian JL, Biscone MJ, et al. Impact of mutations in the 
coreceptor binding site on human immunodeficiency virus type 1 fusion, 
infection, and entry inhibitor sensitivity. J Virol. May 2004;78(10):5476-5485. 
59. Forsell MN, Dey B, Morner A, et al. B cell recognition of the conserved HIV-1 
co-receptor binding site is altered by endogenous primate CD4. PLoS Pathog. 
2008;4(10):e1000171. 
60. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-
1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. 
Science. Jun 28 1996;272(5270):1955-1958. 
61. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is 
mediated by the chemokine receptor CC-CKR-5. Nature. Jun 20 
1996;381(6584):667-673. 
62. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for 
primary isolates of HIV-1. Nature. Jun 20 1996;381(6584):661-666. 
63. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional 
cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 
May 10 1996;272(5263):872-877. 
64. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven-
transmembrane domain receptor involved in fusion and entry of T-cell-tropic 
human immunodeficiency virus type 1 strains. J Virol. Sep 1996;70(9):6288-
6295. 
65. Lehmann MJ, Sherer NM, Marks CB, Pypaert M, Mothes W. Actin- and 
myosin-driven movement of viruses along filopodia precedes their entry into 
cells. J Cell Biol. Jul 18 2005;170(2):317-325. 
66. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV 
envelope glycoprotein. Cell. Apr 18 1997;89(2):263-273. 
67. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic 
structure of the ectodomain from HIV-1 gp41. Nature. May 22 
1997;387(6631):426-430. 
68. Gamble TR, Vajdos FF, Yoo S, et al. Crystal structure of human cyclophilin A 
bound to the amino-terminal domain of HIV-1 capsid. Cell. Dec 27 
1996;87(7):1285-1294. 
69. Fassati A, Goff SP. Characterization of intracellular reverse transcription 
complexes of human immunodeficiency virus type 1. J Virol. Apr 
2001;75(8):3626-3635. 
70. Hu WS, Hughes SH. HIV-1 reverse transcription. Cold Spring Harb Perspect 
Med. Oct 2012;2(10). 
71. Craigie R, Bushman FD. HIV DNA integration. Cold Spring Harb Perspect 
Med. Jul 2012;2(7):a006890. 
72. Schwartz S, Felber BK, Benko DM, Fenyo EM, Pavlakis GN. Cloning and 
functional analysis of multiply spliced mRNA species of human 
immunodeficiency virus type 1. J Virol. Jun 1990;64(6):2519-2529. 
73. Schwartz S, Felber BK, Fenyo EM, Pavlakis GN. Env and Vpu proteins of 
human immunodeficiency virus type 1 are produced from multiple bicistronic 
mRNAs. J Virol. Nov 1990;64(11):5448-5456. 
74. Schwartz S, Felber BK, Pavlakis GN. Expression of human immunodeficiency 
virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. 
Virology. Aug 1991;183(2):677-686. 
   51 
75. Wu Y. HIV-1 gene expression: lessons from provirus and non-integrated DNA. 
Retrovirology. 2004;1:13. 
76. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. 
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. 
Nature. Jan 21 1988;331(6153):280-283. 
77. Farabaugh PJ. Programmed translational frameshifting. Microbiol Rev. Mar 
1996;60(1):103-134. 
78. Stein BS, Engleman EG. Intracellular processing of the gp160 HIV-1 envelope 
precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of 
the Golgi complex. J Biol Chem. Feb 15 1990;265(5):2640-2649. 
79. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold 
Spring Harb Perspect Med. Jul 2012;2(7):a006924. 
80. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. 
Nature. Mar 11 2010;464(7286):217-223. 
81. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and 
antibody seroconversion in plasma donors: implications for diagnosis and 
staging of primary HIV infection. AIDS. Sep 5 2003;17(13):1871-1879. 
82. Jung AC, Paauw DS. Diagnosing HIV-related disease: using the CD4 count as a 
guide. J Gen Intern Med. Feb 1998;13(2):131-136. 
83. Park RA. European AIDS definition. Lancet. Mar 14 1992;339(8794):671. 
84. Ancelle-Park R. Expanded European AIDS case definition. Lancet. Feb 13 
1993;341(8842):441. 
85. Revision of the CDC surveillance case definition for acquired 
immunodeficiency syndrome. Council of State and Territorial Epidemiologists; 
AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep. 
Aug 14 1987;36 Suppl 1:1S-15S. 
86. Smyth RP, Davenport MP, Mak J. The origin of genetic diversity in HIV-1. 
Virus Res. Nov 2012;169(2):415-429. 
87. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. 
Nature. Jan 12 1995;373(6510):123-126. 
88. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from 
HIV-1. Science. Nov 25 1988;242(4882):1171-1173. 
89. Hu WS, Temin HM. Retroviral recombination and reverse transcription. 
Science. Nov 30 1990;250(4985):1227-1233. 
90. Mansky LM, Temin HM. Lower in vivo mutation rate of human 
immunodeficiency virus type 1 than that predicted from the fidelity of purified 
reverse transcriptase. J Virol. Aug 1995;69(8):5087-5094. 
91. Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency 
virus derived from gorillas. Nat Med. Aug 2009;15(8):871-872. 
92. Vallari A, Holzmayer V, Harris B, et al. Confirmation of putative HIV-1 group 
P in Cameroon. J Virol. Feb 2011;85(3):1403-1407. 
93. Vallari A, Bodelle P, Ngansop C, et al. Four new HIV-1 group N isolates from 
Cameroon: Prevalence continues to be low. AIDS Res Hum Retroviruses. Jan 
2010;26(1):109-115. 
94. Mauclere P, Loussert-Ajaka I, Damond F, et al. Serological and virological 
characterization of HIV-1 group O infection in Cameroon. AIDS. Mar 15 
1997;11(4):445-453. 
95. Peeters M, Gueye A, Mboup S, et al. Geographical distribution of HIV-1 group 
O viruses in Africa. AIDS. Mar 15 1997;11(4):493-498. 
96. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in 
humans? Nat Rev Microbiol. Feb 2007;5(2):141-151. 
 52 
97. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. 
Science. Apr 7 2000;288(5463):55-56. 
98. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. 
Evolutionary and immunological implications of contemporary HIV-1 
variation. Br Med Bull. 2001;58:19-42. 
99. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 
Mar 2012;18(3):182-192. 
100. Essex M. Human immunodeficiency viruses in the developing world. Adv Virus 
Res. 1999;53:71-88. 
101. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular 
epidemiology of HIV-1 during 2000-2007. AIDS. Mar 13 2011;25(5):679-689. 
102. Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. The 
emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci U S 
A. Nov 20 2007;104(47):18566-18570. 
103. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of 
HIV-1 subtype diversity. N Engl J Med. Apr 10 2008;358(15):1590-1602. 
104. Renjifo B, Gilbert P, Chaplin B, et al. Preferential in-utero transmission of HIV-
1 subtype C as compared to HIV-1 subtype A or D. AIDS. Aug 20 
2004;18(12):1629-1636. 
105. John-Stewart GC, Nduati RW, Rousseau CM, et al. Subtype C Is associated 
with increased vaginal shedding of HIV-1. J Infect Dis. Aug 1 
2005;192(3):492-496. 
106. Kanki PJ, Hamel DJ, Sankale JL, et al. Human immunodeficiency virus type 1 
subtypes differ in disease progression. J Infect Dis. Jan 1999;179(1):68-73. 
107. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J. Similar rate of disease 
progression among individuals infected with HIV-1 genetic subtypes A-D. 
AIDS. May 28 1999;13(8):901-907. 
108. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression 
of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis. 
Mar 15 2006;42(6):843-852. 
109. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated 
with faster disease progression than subtype A in spite of similar plasma HIV-1 
loads. J Infect Dis. Apr 15 2007;195(8):1177-1180. 
110. Kiwanuka N, Robb M, Laeyendecker O, et al. HIV-1 viral subtype differences 
in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive 
persons in Rakai district, Uganda. J Acquir Immune Defic Syndr. Jun 
2010;54(2):180-184. 
111. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on 
disease progression and response to antiretroviral therapy. J Int AIDS Soc. 
2010;13:4. 
112. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor 
use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan 
cohort. J Acquir Immune Defic Syndr. May 1 2007;45(1):28-33. 
113. Ng OT, Lin L, Laeyendecker O, et al. Increased rate of CD4+ T-cell decline 
and faster time to antiretroviral therapy in HIV-1 subtype CRF01_AE infected 
seroconverters in Singapore. PLoS ONE. 2011;6(1):e15738. 
114. Costello C, Nelson KE, Suriyanon V, et al. HIV-1 subtype E progression 
among northern Thai couples: traditional and non-traditional predictors of 
survival. Int J Epidemiol. Jun 2005;34(3):577-584. 
115. Hudgens MG, Longini IM, Jr., Vanichseni S, et al. Subtype-specific 
transmission probabilities for human immunodeficiency virus type 1 among 
   53 
injecting drug users in Bangkok, Thailand. Am J Epidemiol. Jan 15 
2002;155(2):159-168. 
116. Laurent C, Bourgeois A, Faye MA, et al. No difference in clinical progression 
between patients infected with the predominant human immunodeficiency virus 
type 1 circulating recombinant form (CRF) 02_AG strain and patients not 
infected with CRF02_AG, in Western and West-Central Africa: a four-year 
prospective multicenter study. J Infect Dis. Aug 15 2002;186(4):486-492. 
117. Palm AA, Esbjornsson J, Mansson F, et al. Faster Progression to AIDS and 
AIDS-Related Death Among Seroincident Individuals Infected With 
Recombinant HIV-1 A3/CRF02_AG Compared With Sub-subtype A3. J Infect 
Dis. Aug 30 2013. 
118. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. 
Nature. Jan 15 1998;391(6664):240. 
119. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. Dual 
infection of the central nervous system by AIDS viruses with distinct cellular 
tropisms. Science. May 15 1987;236(4803):819-822. 
120. Gendelman HE, Orenstein JM, Martin MA, et al. Efficient isolation and 
propagation of human immunodeficiency virus on recombinant colony-
stimulating factor 1-treated monocytes. J Exp Med. Apr 1 1988;167(4):1428-
1441. 
121. Gendelman HE, Baca LM, Husayni H, et al. Macrophage-HIV interaction: viral 
isolation and target cell tropism. AIDS. Mar 1990;4(3):221-228. 
122. Chesebro B, Nishio J, Perryman S, et al. Identification of human 
immunodeficiency virus envelope gene sequences influencing viral entry into 
CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol. Nov 
1991;65(11):5782-5789. 
123. Fenyo EM, Albert J, Asjo B. Replicative capacity, cytopathic effect and cell 
tropism of HIV. AIDS. 1989;3 Suppl 1:S5-12. 
124. Koot M, Vos AH, Keet RP, et al. HIV-1 biological phenotype in long-term 
infected individuals evaluated with an MT-2 cocultivation assay. AIDS. Jan 
1992;6(1):49-54. 
125. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss 
RA. The CD4 (T4) antigen is an essential component of the receptor for the 
AIDS retrovirus. Nature. Dec 20-1985 Jan 2 1984;312(5996):763-767. 
126. Verhofstede C, Nijhuis M, Vandekerckhove L. Correlation of coreceptor usage 
and disease progression. Curr Opin HIV AIDS. Sep 2012;7(5):432-439. 
127. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses 
fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion 
cofactors. Cell. Jun 28 1996;85(7):1149-1158. 
128. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and 
CCR5 facilitate infection by primary HIV-1 isolates. Cell. Jun 28 
1996;85(7):1135-1148. 
129. Yost R, Pasquale TR, Sahloff EG. Maraviroc: a coreceptor CCR5 antagonist for 
management of HIV infection. Am J Health Syst Pharm. Apr 15 
2009;66(8):715-726. 
130. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of 
new receptors used by simian and human immunodeficiency viruses. Nature. 
Jul 17 1997;388(6639):296-300. 
131. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in 
coreceptor use correlates with disease progression in HIV-1--infected 
individuals. J Exp Med. Feb 17 1997;185(4):621-628. 
 54 
132. Zhang YJ, Dragic T, Cao Y, et al. Use of coreceptors other than CCR5 by non-
syncytium-inducing adult and pediatric isolates of human immunodeficiency 
virus type 1 is rare in vitro. J Virol. Nov 1998;72(11):9337-9344. 
133. Zerhouni B, Nelson JA, Saha K. Isolation of CD4-independent primary human 
immunodeficiency virus type 1 isolates that are syncytium inducing and acutely 
cytopathic for CD8+ lymphocytes. J Virol. Feb 2004;78(3):1243-1255. 
134. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular 
cloning and functional expression of a new human CC-chemokine receptor 
gene. Biochemistry. Mar 19 1996;35(11):3362-3367. 
135. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. Molecular cloning 
and functional characterization of a novel human CC chemokine receptor 
(CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem. Jul 19 
1996;271(29):17161-17166. 
136. Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J 
Leukoc Biol. Jan 1996;59(1):61-66. 
137. Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage 
inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract 
distinct populations of lymphocytes. J Exp Med. Jun 1 1993;177(6):1821-1826. 
138. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. 
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-
suppressive factors produced by CD8+ T cells. Science. Dec 15 
1995;270(5243):1811-1815. 
139. Mackewicz CE, Barker E, Greco G, Reyes-Teran G, Levy JA. Do beta-
chemokines have clinical relevance in HIV infection? J Clin Invest. Aug 15 
1997;100(4):921-930. 
140. van Rij RP, Blaak H, Visser JA, et al. Differential coreceptor expression allows 
for independent evolution of non-syncytium-inducing and syncytium-inducing 
HIV-1. J Clin Invest. Oct 2000;106(8):1039-1052. 
141. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors 
CXCR4 and CCR5 are differentially expressed and regulated on human T 
lymphocytes. Proc Natl Acad Sci U S A. Mar 4 1997;94(5):1925-1930. 
142. Rubbert A, Combadiere C, Ostrowski M, et al. Dendritic cells express multiple 
chemokine receptors used as coreceptors for HIV entry. J Immunol. Apr 15 
1998;160(8):3933-3941. 
143. Zaitseva M, Blauvelt A, Lee S, et al. Expression and function of CCR5 and 
CXCR4 on human Langerhans cells and macrophages: implications for HIV 
primary infection. Nat Med. Dec 1997;3(12):1369-1375. 
144. He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 
infection of microglia. Nature. Feb 13 1997;385(6617):645-649. 
145. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural 
killer cells in patients receiving highly active antiretroviral therapy. Proc Natl 
Acad Sci U S A. May 14 2002;99(10):7015-7020. 
146. Agace WW, Roberts AI, Wu L, Greineder C, Ebert EC, Parker CM. Human 
intestinal lamina propria and intraepithelial lymphocytes express receptors 
specific for chemokines induced by inflammation. Eur J Immunol. Mar 
2000;30(3):819-826. 
147. Anton PA, Elliott J, Poles MA, et al. Enhanced levels of functional HIV-1 co-
receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. 
AIDS. Aug 18 2000;14(12):1761-1765. 
148. Oppermann M. Chemokine receptor CCR5: insights into structure, function, 
and regulation. Cell Signal. Nov 2004;16(11):1201-1210. 
   55 
149. Farzan M, Mirzabekov T, Kolchinsky P, et al. Tyrosine sulfation of the amino 
terminus of CCR5 facilitates HIV-1 entry. Cell. Mar 5 1999;96(5):667-676. 
150. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in 
human immunodeficiency virus type 1 envelope glycoprotein interactions with 
the CCR5 coreceptor. J Virol. Sep 2002;76(17):8953-8957. 
151. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-
receptor usage and sensitivity to chemokine-mediated suppression. Nat Med. 
Nov 1997;3(11):1259-1265. 
152. Casper C, Naver L, Clevestig P, et al. Coreceptor change appears after immune 
deficiency is established in children infected with different HIV-1 subtypes. 
AIDS Res Hum Retroviruses. Mar 20 2002;18(5):343-352. 
153. Swanstrom R, Coffin J. HIV-1 pathogenesis: the virus. Cold Spring Harb 
Perspect Med. Dec 2012;2(12):a007443. 
154. Isaacman-Beck J, Hermann EA, Yi Y, et al. Heterosexual transmission of 
human immunodeficiency virus type 1 subtype C: Macrophage tropism, 
alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J 
Virol. Aug 2009;83(16):8208-8220. 
155. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological 
phenotype, and evolutionary pathways of transmitted/founder viruses in acute 
and early HIV-1 infection. J Exp Med. Jun 8 2009;206(6):1273-1289. 
156. Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E. Donor and 
recipient envs from heterosexual human immunodeficiency virus subtype C 
transmission pairs require high receptor levels for entry. J Virol. Apr 
2010;84(8):4100-4104. 
157. Ping LH, Joseph SB, Anderson JA, et al. Comparison of Viral Env Proteins 
from Acute and Chronic Infections with Subtype C Human Immunodeficiency 
Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and 
Suggests a New Strategy for Immunogen Design. J Virol. Jul 
2013;87(13):7218-7233. 
158. Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in 
the central nervous system occurs in two distinct cell types. PLoS Pathog. Oct 
2011;7(10):e1002286. 
159. Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disease: 
current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb 
Perspect Med. Jun 2012;2(6):a007120. 
160. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor 
accounts for resistance of some multiply-exposed individuals to HIV-1 
infection. Cell. Aug 9 1996;86(3):367-377. 
161. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection 
and progression to AIDS by a deletion allele of the CKR5 structural gene. 
Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, 
Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE 
Study. Science. Sep 27 1996;273(5283):1856-1862. 
162. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in 
caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor 
gene. Nature. Aug 22 1996;382(6593):722-725. 
163. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in 
HIV-1 transmission and disease progression. Nat Med. Nov 1996;2(11):1240-
1243. 
164. Balotta C, Bagnarelli P, Violin M, et al. Homozygous delta 32 deletion of the 
CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS. Aug 
1997;11(10):F67-71. 
 56 
165. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous 
for CCR5 delta 32. Lancet. Apr 26 1997;349(9060):1219. 
166. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 
infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. 
Lancet. Apr 26 1997;349(9060):1219-1220. 
167. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of 
symptomatic West Nile virus infection. J Exp Med. Jan 23 2006;203(1):35-40. 
168. Bracci PM, Skibola CF, Conde L, et al. Chemokine polymorphisms and 
lymphoma: a pooled analysis. Leuk Lymphoma. Mar 2010;51(3):497-506. 
169. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a 
ligand for LESTR/fusin and blocks HIV-1 entry. Nature. Aug 29 
1996;382(6594):829-833. 
170. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the 
ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. 
Nature. Aug 29 1996;382(6594):833-835. 
171. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a 
pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. Mar 15 
1994;91(6):2305-2309. 
172. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly 
efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). 
J Exp Med. Sep 1 1996;184(3):1101-1109. 
173. Ostrowski MA, Chun TW, Justement SJ, et al. Both memory and 
CD45RA+/CD62L+ naive CD4(+) T cells are infected in human 
immunodeficiency virus type 1-infected individuals. J Virol. Aug 
1999;73(8):6430-6435. 
174. Nicholson JK, Browning SW, Hengel RL, et al. CCR5 and CXCR4 expression 
on memory and naive T cells in HIV-1 infection and response to highly active 
antiretroviral therapy. J Acquir Immune Defic Syndr. Jun 1 2001;27(2):105-115. 
175. Tchou I, Misery L, Sabido O, et al. Functional HIV CXCR4 coreceptor on 
human epithelial Langerhans cells and infection by HIV strain X4. J Leukoc 
Biol. Aug 2001;70(2):313-321. 
176. Valentin A, Trivedi H, Lu W, Kostrikis LG, Pavlakis GN. CXCR4 mediates 
entry and productive infection of syncytia-inducing (X4) HIV-1 strains in 
primary macrophages. Virology. Apr 10 2000;269(2):294-304. 
177. Di Marzio P, Tse J, Landau NR. Chemokine receptor regulation and HIV type 1 
tropism in monocyte-macrophages. AIDS Res Hum Retroviruses. Jan 20 
1998;14(2):129-138. 
178. Verani A, Gras G, Pancino G. Macrophages and HIV-1: dangerous liaisons. 
Mol Immunol. Feb 2005;42(2):195-212. 
179. Tan Q, Zhu Y, Li J, et al. Structure of the CCR5 chemokine receptor-HIV entry 
inhibitor maraviroc complex. Science. Sep 20 2013;341(6152):1387-1390. 
180. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR 
with small-molecule and cyclic peptide antagonists. Science. Nov 19 
2010;330(6007):1066-1071. 
181. Brelot A, Heveker N, Montes M, Alizon M. Identification of residues of 
CXCR4 critical for human immunodeficiency virus coreceptor and chemokine 
receptor activities. J Biol Chem. Aug 4 2000;275(31):23736-23744. 
182. Chabot DJ, Chen H, Dimitrov DS, Broder CC. N-linked glycosylation of 
CXCR4 masks coreceptor function for CCR5-dependent human 
immunodeficiency virus type 1 isolates. J Virol. May 2000;74(9):4404-4413. 
183. Schuitemaker H, van 't Wout AB, Lusso P. Clinical significance of HIV-1 
coreceptor usage. J Transl Med. 2011;9 Suppl 1:S5. 
   57 
184. Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, 
Schuitemaker H. Increased neutralization sensitivity of recently emerged 
CXCR4-using human immunodeficiency virus type 1 strains compared to 
coexisting CCR5-using variants from the same patient. J Virol. Jan 
2007;81(2):525-531. 
185. Bunnik EM, Swenson LC, Edo-Matas D, et al. Detection of inferred CCR5- and 
CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep 
pyrosequencing. PLoS Pathog. Jun 2011;7(6):e1002106. 
186. Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human 
immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism 
and heterogeneous composition of viral populations. J Virol. Aug 
2007;81(15):7885-7893. 
187. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF. 
Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-
tropic HIV from the plasma of drug-naive individuals. AIDS. Jul 31 
2008;22(12):1425-1431. 
188. Rucker J, Edinger AL, Sharron M, et al. Utilization of chemokine receptors, 
orphan receptors, and herpesvirus-encoded receptors by diverse human and 
simian immunodeficiency viruses. J Virol. Dec 1997;71(12):8999-9007. 
189. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 
loop as the primary determinant of cell tropism in HIV-1. Science. Jul 5 
1991;253(5015):71-74. 
190. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal 
requirements for the human immunodeficiency virus type 1 V3 domain to 
support the syncytium-inducing phenotype: analysis by single amino acid 
substitution. J Virol. Nov 1992;66(11):6777-6780. 
191. de Jong JJ, Goudsmit J, Keulen W, et al. Human immunodeficiency virus type 
1 clones chimeric for the envelope V3 domain differ in syncytium formation 
and replication capacity. J Virol. Feb 1992;66(2):757-765. 
192. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence 
variation in the third variable domain of the human immunodeficiency virus 
type 1 gp120 molecule. J Virol. May 1992;66(5):3183-3187. 
193. Shioda T, Levy JA, Cheng-Mayer C. Small amino acid changes in the V3 
hypervariable region of gp120 can affect the T-cell-line and macrophage 
tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 
Oct 15 1992;89(20):9434-9438. 
194. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human 
immunodeficiency virus isolates from different patients exhibit unusual V3 
envelope sequence homogeneity in comparison with T-cell-tropic isolates: 
definition of critical amino acids involved in cell tropism. J Virol. Nov 
1992;66(11):6547-6554. 
195. Catasti P, Fontenot JD, Bradbury EM, Gupta G. Local and global structural 
properties of the HIV-MN V3 loop. J Biol Chem. Feb 3 1995;270(5):2224-
2232. 
196. Rini JM, Stanfield RL, Stura EA, Salinas PA, Profy AT, Wilson IA. Crystal 
structure of a human immunodeficiency virus type 1 neutralizing antibody, 
50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci U S A. 
Jul 1 1993;90(13):6325-6329. 
197. Tugarinov V, Zvi A, Levy R, Hayek Y, Matsushita S, Anglister J. NMR 
structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface 
important for co-receptor binding. Structure. Apr 15 2000;8(4):385-395. 
 58 
198. Huang CC, Tang M, Zhang MY, et al. Structure of a V3-containing HIV-1 
gp120 core. Science. Nov 11 2005;310(5750):1025-1028. 
199. Labrosse B, Treboute C, Brelot A, Alizon M. Cooperation of the V1/V2 and V3 
domains of human immunodeficiency virus type 1 gp120 for interaction with 
the CXCR4 receptor. J Virol. Jun 2001;75(12):5457-5464. 
200. Rizzuto CD, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 
glycoprotein structure involved in chemokine receptor binding. Science. Jun 19 
1998;280(5371):1949-1953. 
201. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. 
Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res 
Hum Retroviruses. Mar 2007;23(3):415-426. 
202. De Wolf F, Hogervorst E, Goudsmit J, et al. Syncytium-inducing and non-
syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes 
other than B: phenotypic and genotypic characteristics. WHO Network for HIV 
Isolation and Characterization. AIDS Res Hum Retroviruses. Nov 
1994;10(11):1387-1400. 
203. Verrier F, Borman AM, Brand D, Girard M. Role of the HIV type 1 
glycoprotein 120 V3 loop in determining coreceptor usage. AIDS Res Hum 
Retroviruses. May 20 1999;15(8):731-743. 
204. Hu QX, Barry AP, Wang ZX, Connolly SM, Peiper SC, Greenberg ML. 
Evolution of the human immunodeficiency virus type 1 envelope during 
infection reveals molecular corollaries of specificity for coreceptor utilization 
and AIDS pathogenesis. J Virol. Dec 2000;74(24):11858-11872. 
205. Milich L, Margolin B, Swanstrom R. V3 loop of the human immunodeficiency 
virus type 1 Env protein: interpreting sequence variability. J Virol. Sep 
1993;67(9):5623-5634. 
206. Milich L, Margolin BH, Swanstrom R. Patterns of amino acid variability in 
NSI-like and SI-like V3 sequences and a linked change in the CD4-binding 
domain of the HIV-1 Env protein. Virology. Dec 8 1997;239(1):108-118. 
207. Ping LH, Nelson JA, Hoffman IF, et al. Characterization of V3 sequence 
heterogeneity in subtype C human immunodeficiency virus type 1 isolates from 
Malawi: underrepresentation of X4 variants. J Virol. Aug 1999;73(8):6271-
6281. 
208. Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, Paxton WA. N-
linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major 
determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem. Apr 20 
2001;276(16):13433-13441. 
209. Polzer S, Dittmar MT, Schmitz H, et al. Loss of N-linked glycans in the V3-
loop region of gp120 is correlated to an enhanced infectivity of HIV-1. 
Glycobiology. Jan 2001;11(1):11-19. 
210. Polzer S, Dittmar MT, Schmitz H, Schreiber M. The N-linked Glycan g15 
within the V3 Loop of the HIV-1 External Glycoprotein gp120 Affects 
Coreceptor Usage, Cellular Tropism, and Neutralization. Virology. 
2002;304(1):70-80. 
211. Koch M, Pancera M, Kwong PD, et al. Structure-based, targeted 
deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and 
antibody recognition. Virology. Sep 1 2003;313(2):387-400. 
212. Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, Cho MW. N-
linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of 
dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect 
coreceptor usage and cellular tropism. J Virol. Jul 2001;75(13):5998-6006. 
   59 
213. Biscone MJ, Miamidian JL, Muchiri JM, et al. Functional impact of HIV 
coreceptor-binding site mutations. Virology. Jul 20 2006;351(1):226-236. 
214. Jansson M, Backstrom E, Scarlatti G, et al. Length variation of glycoprotein 
120 V2 region in relation to biological phenotypes and coreceptor usage of 
primary HIV type 1 isolates. AIDS Res Hum Retroviruses. Oct 10 
2001;17(15):1405-1414. 
215. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA. 
Intrapatient alterations in the human immunodeficiency virus type 1 gp120 
V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition 
by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal 
antibodies. J Virol. Jan 2004;78(1):524-530. 
216. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human 
immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness 
mutations compensate for V3 loss-of-fitness mutations. J Virol. Jan 
2006;80(2):750-758. 
217. Huang W, Toma J, Fransen S, et al. Coreceptor tropism can be influenced by 
amino acid substitutions in the gp41 transmembrane subunit of human 
immunodeficiency virus type 1 envelope protein. J Virol. Jun 
2008;82(11):5584-5593. 
218. Cecilia D, KewalRamani VN, O'Leary J, et al. Neutralization profiles of 
primary human immunodeficiency virus type 1 isolates in the context of 
coreceptor usage. J Virol. Sep 1998;72(9):6988-6996. 
219. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and 
characterization of transmitted and early founder virus envelopes in primary 
HIV-1 infection. Proc Natl Acad Sci U S A. May 27 2008;105(21):7552-7557. 
220. Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder 
HIV-1. Proc Natl Acad Sci U S A. Apr 23 2013;110(17):6626-6633. 
221. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of 
a novel single-cycle recombinant-virus assay to determine human 
immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents 
Chemother. Feb 2007;51(2):566-575. 
222. Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatment-
experienced subjects, as determined by an enhanced-sensitivity coreceptor 
tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis. Dec 
1 2009;200(11):1724-1728. 
223. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb J. An enhanced sensitivity 
Trofile HIV coreceptor tropism assay for selecting patients for therapy with 
entry inhibitors targeting CCR5: a review of analytical and clinical studies. J 
Viral Entry. 2009;3:94-102. 
224. Koot M, van Leeuwen R, de Goede RE, et al. Conversion rate towards a 
syncytium-inducing (SI) phenotype during different stages of human 
immunodeficiency virus type 1 infection and prognostic value of SI phenotype 
for survival after AIDS diagnosis. J Infect Dis. Jan 1999;179(1):254-258. 
225. Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of 
CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort 
study. J Infect Dis. Oct 15 2008;198(8):1104-1112. 
226. Wambui V, Kiptoo M, Kinyua J, et al. Predicted HIV-1 coreceptor usage 
among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic. 
AIDS Res Ther. 2012;9(1):22. 
227. Yu XF, Wang Z, Beyrer C, et al. Phenotypic and genotypic characteristics of 
human immunodeficiency virus type 1 from patients with AIDS in northern 
Thailand. J Virol. Aug 1995;69(8):4649-4655. 
 60 
228. Utaipat U, Duerr A, Rudolph DL, et al. Coreceptor utilization of HIV type 1 
subtype E viral isolates from Thai men with HIV type 1-infected and uninfected 
wives. AIDS Res Hum Retroviruses. Jan 1 2002;18(1):1-11. 
229. To SW, Chen JH, Wong KH, Chan KC, Chen Z, Yam WC. Determination of 
the High Prevalence of Dual/Mixed- or X4-Tropism Among HIV Type 1 
CRF01_AE in Hong Kong by Genotyping and Phenotyping Methods. AIDS Res 
Hum Retroviruses. May 31 2013. 
230. Tscherning C, Alaeus A, Fredriksson R, et al. Differences in chemokine 
coreceptor usage between genetic subtypes of HIV-1. Virology. Feb 15 
1998;241(2):181-188. 
231. Abebe A, Demissie D, Goudsmit J, et al. HIV-1 subtype C syncytium- and non-
syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients 
with AIDS. AIDS. Jul 30 1999;13(11):1305-1311. 
232. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, Fenyo EM. Phenotypic 
characteristics of human immunodeficiency virus type 1 subtype C isolates of 
Ethiopian AIDS patients. AIDS Res Hum Retroviruses. May 1 1999;15(7):647-
653. 
233. Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE. Extreme 
genetic divergence is required for coreceptor switching in HIV-1 subtype C. J 
Acquir Immune Defic Syndr. Jan 1 2011;56(1):9-15. 
234. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, 
Katzenstein DA. High Frequency of Syncytium-Inducing and CXCR4-Tropic 
Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected 
Patients Receiving Antiretroviral Treatment. Journal of Virology. 
2003;77(13):7682-7688. 
235. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, 
Papathanasopoulos MA. Emergence of X4 usage among HIV-1 subtype C: 
evidence for an evolving epidemic in South Africa. AIDS. Apr 23 
2008;22(7):896-899. 
236. Singh A, Sunpath H, Green TN, et al. Drug resistance and viral tropism in HIV-
1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for 
future treatment options. J Acquir Immune Defic Syndr. Nov 1 2011;58(3):233-
240. 
237. Green TN, Archary M, Gordon ML, et al. Drug resistance and coreceptor usage 
in HIV type 1 subtype C-infected children initiating or failing highly active 
antiretroviral therapy in South Africa. AIDS Res Hum Retroviruses. Apr 
2012;28(4):324-332. 
238. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and 
therapeutic insights. Nat Rev Microbiol. Apr 2012;10(4):279-290. 
239. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb 
Perspect Med. Apr 2012;2(4):a007161. 
240. Sarafianos SG, Das K, Clark AD, Jr., et al. Lamivudine (3TC) resistance in 
HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino 
acids. Proc Natl Acad Sci U S A. Aug 31 1999;96(18):10027-10032. 
241. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 
1 mutations selected in patients failing efavirenz combination therapy. 
Antimicrob Agents Chemother. Sep 2000;44(9):2475-2484. 
242. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in 
HIV protease confers resistance to ritonavir. Nat Med. Jul 1996;2(7):760-766. 
243. Maeda K, Das D, Nakata H, Mitsuya H. CCR5 inhibitors: emergence, success, 
and challenges. Expert Opin Emerg Drugs. Jun 2012;17(2):135-145. 
   61 
244. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and 
antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 
infection. J Acquir Immune Defic Syndr. Oct 1 2004;37(2):1253-1262. 
245. Fransen S, Bridger G, Whitcomb JM, et al. Suppression of dualtropic human 
immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is 
associated with efficiency of CXCR4 use and baseline virus composition. 
Antimicrob Agents Chemother. Jul 2008;52(7):2608-2615. 
246. Moyle G, DeJesus E, Boffito M, et al. Proof of activity with AMD11070, an 
orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis. Mar 
15 2009;48(6):798-805. 
247. FDA approves maraviroc tablets. AIDS Patient Care STDS. Sep 
2007;21(9):702. 
248. Caseiro MM, Nelson M, Diaz RS, et al. Vicriviroc plus optimized background 
therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final 
results of two randomized phase III trials. J Infect. Oct 2012;65(4):326-335. 
249. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical 
trials of aplaviroc (GW873140). Antimicrob Agents Chemother. Mar 
2008;52(3):858-865. 
250. Klibanov OM, Williams SH, Iler CA. Cenicriviroc, an orally active CCR5 
antagonist for the potential treatment of HIV infection. Curr Opin Investig 
Drugs. Aug 2010;11(8):940-950. 
251. Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy 
of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 
infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir 
Immune Defic Syndr. Dec 15 2010;55(5):558-564. 
252. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in 
combination with zidovudine-lamivudine, for the treatment of antiretroviral-
naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. Mar 15 
2010;201(6):803-813. 
253. Wilkin TJ, Goetz MB, Leduc R, et al. Reanalysis of coreceptor tropism in HIV-
1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect 
Dis. Apr 1 2011;52(7):925-928. 
254. Vandekerckhove LPR, Wensing AMJ, Kaiser R, et al. European guidelines on 
the clinical management of HIV-1 tropism testing. The Lancet Infectious 
Diseases. 2011;11(5):394-407. 
255. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism 
assay: a retrospective analysis using screening samples from the A4001029 and 
MOTIVATE studies. AIDS. Oct 23 2010;24(16):2517-2525. 
256. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in 
phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 
antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. Mar 
2007;81(5):2359-2371. 
257. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial 
patients treated in Botswana's National Antiretroviral Treatment Program. 
AIDS. Nov 12 2008;22(17):2303-2311. 
258. Ministry of Health, The Republich of Botswana, MASA. 2012 Botswana 
National HIV & AIDS Treatment Guidelines. 2012. <http://www.aidstar-
one.com/sites/default/files/Botswana_2012_tagged.pdf> 
259. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype 
prediction. AIDS Res Hum Retroviruses. Feb 2003;19(2):145-149. 
260. Jensen MA, Li FS, van 't Wout AB, et al. Improved Coreceptor Usage 
Prediction and Genotypic Monitoring of R5-to-X4 Transition by Motif Analysis 
 62 
of Human Immunodeficiency Virus Type 1 env V3 Loop Sequences. Journal of 
Virology. 2003;77(24):13376-13388. 
261. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction 
of HIV coreceptor usage. Nat Biotechnol. Dec 2007;25(12):1407-1410. 
262. Cashin K, Gray LR, Jakobsen MR, Sterjovski J, Churchill MJ, Gorry PR. 
CoRSeqV3-C: a novel HIV-1 subtype C specific V3 sequence based coreceptor 
usage prediction algorithm. Retrovirology. 2013;10:24. 
263. Raymond S, Delobel P, Chaix ML, et al. Genotypic prediction of HIV-1 
subtype D tropism. Retrovirology. 2011;8:56. 
264. Raymond S, Delobel P, Rogez S, et al. Genotypic prediction of HIV-1 CRF01-
AE tropism. J Clin Microbiol. Feb 2013;51(2):564-570. 
265. Ndung'u T, Sepako E, McLane MF, et al. HIV-1 subtype C in vitro growth and 
coreceptor utilization. Virology. Apr 10 2006;347(2):247-260. 
266. Clevestig P, Maljkovic I, Casper C, et al. The X4 phenotype of HIV type 1 
evolves from R5 in two children of mothers, carrying X4, and is not linked to 
transmission. AIDS Res Hum Retroviruses. May 2005;21(5):371-378. 
267. Leitner T, Korovina G, Marquina S, Smolskaya T, Albert J. Molecular 
epidemiology and MT-2 cell tropism of Russian HIV type 1 variant. AIDS Res 
Hum Retroviruses. Nov 20 1996;12(17):1595-1603. 
268. Brinchmann JE, Albert J, Vartdal F. Few infected CD4+ T cells but a high 
proportion of replication-competent provirus copies in asymptomatic human 
immunodeficiency virus type 1 infection. J Virol. Apr 1991;65(4):2019-2023. 
269. Rodrigo AG, Goracke PC, Rowhanian K, Mullins JI. Quantitation of target 
molecules from polymerase chain reaction-based limiting dilution assays. AIDS 
Res Hum Retroviruses. Jun 10 1997;13(9):737-742. 
270. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human 
immunodeficiency virus type 1 drug resistance mutations in treatment-
experienced patients are missed by standard genotype analysis. J Clin 
Microbiol. Jan 2005;43(1):406-413. 
271. Marshall RD. Glycoproteins. Annu Rev Biochem. 1972;41:673-702. 
272. Gavel Y, von Heijne G. Sequence differences between glycosylated and non-
glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein 
engineering. Protein Eng. Apr 1990;3(5):433-442. 
273. Mellquist JL, Kasturi L, Spitalnik SL, Shakin-Eshleman SH. The amino acid 
following an asn-X-Ser/Thr sequon is an important determinant of N-linked 
core glycosylation efficiency. Biochemistry. May 12 1998;37(19):6833-6837. 
274. Kasturi L, Chen H, Shakin-Eshleman SH. Regulation of N-linked core 
glycosylation: use of a site-directed mutagenesis approach to identify Asn-Xaa-
Ser/Thr sequons that are poor oligosaccharide acceptors. Biochem J. Apr 15 
1997;323 ( Pt 2):415-419. 
275. Losman B, Biller M, Olofsson S, et al. The N-linked glycan of the V3 region of 
HIV-1 gp120 and CXCR4-dependent multiplication of a human 
immunodeficiency virus type 1 lymphocyte-tropic variant. FEBS Lett. Jul 2 
1999;454(1-2):47-52. 
276. Parczewski M, Leszczyszyn-Pynka M, Urbanska A, Bander D, Boron-
Kaczmarska A. Genotypic tropism of antiretroviral-treated patients with drug 
resistant HIV-1. J Med Virol. Nov 2011;83(11):1869-1875. 
277. Lin NH, Smeaton LM, Giguel F, et al. Prevalence and clinical associations of 
CXCR4-using HIV-1 among treatment-naive subtype C-infected women in 
Botswana. J Acquir Immune Defic Syndr. May 1 2011;57(1):46-50. 
   63 
278. Wagner TA, Frenkel LM. Potential limitation of CCR5 antagonists: drug 
resistance more often linked to CXCR4-utilizing than to CCR5-utilizing HIV-1. 
AIDS. Nov 12 2008;22(17):2393-2395. 
279. O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J. 
Monitoring resistance to human immunodeficiency virus type 1 protease 
inhibitors by pyrosequencing. J Clin Microbiol. Feb 2001;39(2):464-473. 
280. Archer J, Braverman MS, Taillon BE, et al. Detection of low-frequency 
pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with 
ultra-deep pyrosequencing. AIDS. Jun 19 2009;23(10):1209-1218. 
281. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Genetic and 
phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the 
Italian example. Retrovirology. 2007;4:34. 
 
 
